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Abstract 
Objective. The objective of this dissertation is to (I) explore the temporal 
survival and identify prognostic factors in patients with antineutrophil 
cytoplasmic antibody (ANCA)-associated vasculitis with renal affection, (II) 
validate a recently proposed histopathological classification model, and (III) 
quantify the incidence of malignancy in this patient group. 
 
Methods. Patients with biopsy-proven pauci-immune crescentic 
glomerulonephritis and positive ANCA serology were included from the 
Norwegian Kidney Biopsy Registry from (I/III) 1988 through 2012 and (II) 
1991 through 2012. Using the unique 11-digit personal number, end-stage 
renal failure and death were identified by record-linkage with the Norwegian 
Renal Registry and the Norwegian Population Registry. The cause of death 
was obtained from the Cause of Death Registry, Statistics Norway. (II) All 
biopsies were scored according to the histopathological classification model 
(focal, mixed, crescentic, and sclerotic class) by an experienced 
nephropathologist. A receiver operator characteristic curve was calculated to 
test the performance of the classification model. (III) The incidence of cancer 
was identified by cross-linkage with the Norwegian Cancer Registry.  
 
Results. (I) Four hundred and fifty-five patients were included. One hundred 
and twenty-four (27%) developed end-stage renal disease, and 165 (36%) 
deaths occurred. Independent negative predictors were low baseline 
estimated-glomerular filtration rate < 15 ml/min per 1.73 m2, older age (> 60 
years) and baseline serum albumin < 30 g/L. Patients diagnosed between 
2003 and 2012 had better baseline renal function than those diagnosed 
between 1988 and 2002 (27 versus 37 ml/min per 1.73 m2) and more 
favourable end-stage renal disease-free survival (1-year risk, 19% versus 
13%; 10-year risk, 37% versus 26%). Compared to the general population, 
the risk of mortality was 2.8-fold higher (95% confidence interval, 2.4 to 3.3). 
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(II) The histopathologic classification model was validated in 250 patients. 
The model could successfully predict renal survival, with the focal and 
sclerotic classes having the best and worst outcome (hazard ratio, 9.65; 95% 
confidence interval, 2.4 to 39.2), respectively. The area under the curve in the 
receiver operator characteristic curve was calculated to be 0.72 (95% 
confidence interval, 0.7 to 0.8). (III) Four hundred and nineteen patients were 
included in the study cohort. The standardised incidence ratio for the 
development of at least one cancer in this patient cohort compared to the 
general population was 1.09 (95% confidence interval, 0.8 to 1.5). There were  
large number of cases of non-melanoma skin cancers and bone marrow 
malignancies, with a standardised incidence ratio of 3.40 (95% confidence 
interval, 1.6 to 7.1) and 3.52 (95% confidence interval, 1.3 to 9.4), 
respectively.    
 
Conclusion. (I) Although the prognosis improved in patients with ANCA-
associated glomerulonephritis, mortality remains high compared to the 
general population. Improvement in prognosis might be due to earlier 
diagnosis before irreversible organ damage occurs. (II) The histopathological 
classification model is of average quality as a predictor of end-stage renal 
disease. Patients with kidney biopsies classified as sclerotic class are 
particularly at risk of developing end-stage renal disease. (III) The risk of 
malignancy was not significantly increased in this patient cohort compared to 
the general population. Non-melanoma skin cancer was the most frequent 
malignancy, and a major contributor to the observed overall cancer 
occurrence in this patient population.  
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Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is 
a primary systemic autoimmune disease, characterised by necrotising 
inflammation affecting small to medium size blood vessels in the body. It is a 
clinical and pathological syndrome consisting primarily of granulomatosis with 
polyangiitis (GPA) (formerly known as Wegener’s granulomatosis (WG)) and 
microscopic polyangiitis (MPA), and less commonly, eosinophilic 
granulomatosis with polyangiitis (EGPA) (formerly known as Churg-Strauss 
syndrome). The cause is still unknown, but most patients have circulating 
autoantibodies (ANCAs) in their blood sera. These autoantibodies are 
pathogenic and directed towards neutrophil granulocytes and monocytes, and 
activate these by binding to the surface-near antigens, myeloperoxidase 
(MPO) and serine protease 3 (PR3). Clinical symptoms may vary and affect 
many organs, but left untreated, lead to rapid onset of renal loss and 
respiratory failure. The kidney is the most prevalent target of injury, resulting 
in a rapid progressive glomerulonephritis (GN). Introduction of 
immunosuppressive therapy in the 1960s and ANCA serology in the 1980s 
has revolutionised the diagnostic process and improved the prognosis over 
the last 5 decades. AAV is currently a chronic disease with a remitting-
relapsing course. The mortality rate is still higher than the general population, 
and treatment-related adverse effects are a major concern (1-3).  
Due to the rare nature of the disease, data on prognosis is scarce in the 
literature. Long-term trends in mortality and morbidity and identifying 
prognostic parameters of outcome are targets for this thesis.  
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1.2. Classification  
Historically, Kussmaul and Maier reported the first case study of vasculitis 
in 1866 (4). They observed nodular inflammation in small- and medium-sized 
blood vessels in a patient that presented with nonspecific signs, such as 
fever, anorexia, myalgia, abdominal pain, paraesthesia, and oliguria. The 
condition was named periarteritis nodosa, which was renamed as polyarteritis 
nodosa. Over time, vasculitis targeting predominantly small- to medium-sized 
vessels was identified and separated from polyarteritis nodosa. These were 
highlighted by Godman and Churg in 1957 as WG, “microscopic form of 
periarteritis” (MPA), and Churg-Strauss syndrome (1, 5). 
 
The ACR classification 1990 
In 1990, the American College of Rheumatology (ACR) published the first 
standardised classification of vasculitis (6-8). The classification criteria 
consisted of 7 diagnoses: WG, polyarteritis nodosa, Churg-Strauss 
syndrome, hypersensitivity vasculitis, Henoch-Schönlein purpura, giant cell 
arteritis, and Takayasu arteritis. WG was diagnosed on the presence of two 
or more of the following criteria: 1) nasal or oral inflammation, 2) chest 
radiograph showing nodules, infiltrates, or cavities, 3) haematuria or red cell 
casts in urine sediment, and 4) granulomatous inflammation on biopsy. It is 
important to mention that the ACR classification tools were intended to 
distinguish patients in epidemiological research, and had little clinical 
diagnostic value. Additionally, the classification did not include ANCA 
serology as criteria, or contained any classification criteria for MPA.  
 
The Chapel Hill Consensus Conference 1994 and 2012 definitions  
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The Chapel Hill Consensus Conference in 1994 aimed at defining the 
nomenclature of primary systemic vasculitis (9). The vasculitis was classified 
according to the smallest affected vessel, i.e. small vessel vasculitis affects 
predominantly intraparenchymal capillaries, venules, arterioles, and arteries. 
The nomenclature introduced MPA and surrogate markers for vasculitis (e.g. 
haematuria, proteinuria, and the presence of red cell casts in urine sediment 
are diagnostic markers for glomerulonephritis). Polyarteritis nodosa was 
distinguished from MPA by the absence of small vessel inflammation. 
Moreover, WG was restricted to vessels with granulomatous inflammation, 
while non-granulomatous lesions characterised MPA. The definitions were 
revised in 2012 with the inclusion of ANCA serology (10). The small vessel 
vasculitis was divided into ANCA-associated (GPA, MPA, EGPA, and single 
organ AAV) with paucity of immune deposits in the vessel wall, and immune 
deposition rich immune-complex mediated vasculitis. Importantly, it was 
emphasised that the definitions were not valid as classification or diagnostic 
criteria for vasculitis. The 2012 definition of AAV is depicted in Table 1.  
Table 1. The Chapel Hill Consensus Conference 2012 definition of AAV (10) 
General Necrotising vasculitis, few or no immune deposits, affects 
predominantly small vessels, associated with ANCA (MPO-, PR3-, 
or negative ANCA) 
MPA Necrotising vasculitis of small and medium vessels may occur. 
Necrotising GN is very common, pulmonary capillaritis often occurs. 
Granulomatous inflammation is absent.  
GPA Necrotising granulomatous inflammation usually involving upper 
and lower respiratory tract. Necrotising GN is frequent.  
EGPA Eosinophil-rich and necrotising granulomatous inflammation usually 
involving the respiratory tract and associated with asthma and 
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eosinophilia. ANCAs are more common when GN is present.  
 
The European Medicines Agency (EMEA) algorithm 2007 
Due to the absence of classification criteria of MPA in the ACR criteria and 
the CHCC 1994 definitions, in 2007, the EMEA developed a stepwise 
consensus algorithm for classifying AAV and polyarteritis nodosa. The 
purpose was to incorporate the ACR criteria and the CHCC 1994 definitions 
into a harmonised and standardised system to be utilised in epidemiological 
studies (11). The ACR criteria was first preferred for classifying Churg-
Strauss Syndrome and WG, whereas CHCC 1994 defined MPA after the 
exclusion of the previous conditions.   
1.3. Epidemiology  
Incidence and prevalence 
The overall incidence of AAV in Europe has been estimated to be about 
6-23 cases per million population (12-15). In a recent biopsy-based study of 
Swedish patients with ANCA-associated GN (ANCA-GN), the annual 
incidence was estimated to be 13.2 cases per million population (16). In 
comparison, in Norwegian patients with GPA, the annual incidence rate was 
estimated to be 9.3 cases per million population (17). The incidence rate is 
higher in GPA than MPA, 11.3 versus 5.9 cases per million population per 
year, but this varies in the literature. EGPA is the least frequent clinical 
phenotype; its highest annual incidence rate was estimated to be 2.7 cases 
per million population in the UK (18).  
Longitudinal epidemiology studies have shown an increased incidence 
of AAV since the early 1980s. Reports from the United Kingdom have 
observed a combined annual incidence of GPA and MPA of 1.5 in 1980-1986 
to 6.1 cases per million population by the end of 1989 (19, 20). This finding 
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was comparable with a Swedish study by Knight et al., who reported an 
increasing incidence from 3 to 8 cases per million population per year (21). 
This trend might reflect an actual increase in incidence, but recent papers 
have shown a stable rate over the last decade (15, 22-27). Alternatively, the 
increase in the incidence might be due to the introduction of ANCA serology 
and more awareness of the disease among healthcare workers, which led to 
an increased case capture. 
The prevalence of AAV in Europe is estimated to be 45-184 cases per 
million population (14, 15, 27, 28). The prevalence has also increased during 
the last few decades, proportionately to the incidence rate. In Norway, the 
prevalence of GPA has increased from 30.4 in 1988 to 95.1 cases per million 
population in 1998 (17). This trend might be a result of increased patient 
survival and improved case identification. Data on the prevalence of MPA is 
scarce but has been reported to range from 19.3 to 94 cases per million 
population (15, 20, 29). The prevalence of GPA is somewhat lower in 
southern Europe, reported to be 24 in France (30) and 42 cases per million 
population in Turkey (15), respectively. This observation strengthens the 
assumption of a north-south gradient where GPA is more prevalent in 
Scandinavian countries. The age-specific peak incidence is in the age groups 
55-64 (22) and 65-74 years (20). AAV affects both genders equally and most 
patients are Caucasian. Several studies from Europe and Asia have shown 
that AAV was twice as prevalent among Europeans than non-Europeans (13, 
30, 31). 
 
Geographical and seasonal variations 
Watts and colleagues described a difference in incidence between GPA 
and MPA in northern and southern Europe. The incidence of GPA was higher 
in the northern region, while MPA was more frequent in southern Europe, 
which is called a north-south gradient (12). Comparable observation was also 
 18 
seen in New Zealand, with a 2-3 times higher incidence of GPA in southern 
latitudes compared to northernmost latitudes (31). Possible explanations for 
the north-south gradient might be due to different UV radiation exposure or 
genetic variations between ethnicities. Conversely, this gradient was not 
observed in other studies from the southern hemisphere, showing a 
comparable incidence rate of GPA to reports from northern Norway (24, 32). 
Similar results have also been evident in a Swedish report, with an incidence 
rate of MPA similar to rates from southern Europe (26). Moreover, MPA and 
MPO-ANCA are more common in Asian countries, like Japan and China, 
compared to Europe (33).  
Studies have also suggested seasonal and periodic fluctuations in onset of 
AAV, but contradictory results have been reported on this topic. Incidence 
peaking every 3-4 years and more symptoms occurring during dark winter 
periods might reflect environmental risk factors such as viral infections, i.e. 
influenza, while disease onset clustering around spring and summer periods 
is suggested to be associated with allergic inflammation. Pertinently, studies 
from France (34) and Japan (35) showed that symptoms developed 
predominantly during summer periods. In contrast, other papers could not 
demonstrate any seasonal fluctuation in disease onset (17, 26, 36). 
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1.4. Aetiology  
Genetic Aspects 
The cause of AAV remains unknown but is likely multifactorial, involving 
both environmental and genetic factors. Altered gene expression might lead 
to aberrant protein synthesis and/or function. Results from recent genetic 
studies support the role of a dysregulated inflammatory process involving the 
major histocompatibility complex system, alpha-1-antitrypsin, and cytotoxic T 
lymphocyte associated antigen-4 in the pathogenesis of AAV. The two major 
clinical syndromes of AAV, GPA and MPA, have been recently described in 
genome-wide association studies as aetiologically distinct diseases. The 
correlation between candidate genes and disease were differentiated, 
particularly with PR3 and MPO disease subsets (37-40). Furthermore, in a 
large meta-analysis, investigators identified 33 genetic variants that were 
associated with AAV. A subdivision of AAV broken down by PR3 and MPO, 
had a stronger genetic correlation than with the clinical syndrome of GPA and 
MPA (41). Familial clustering of these risk alleles might also increase the 
susceptibility to develop AAV (42-45). 
The human leukocyte antigen (HLA) system is crucial in disease 
aetiopathogenesis in AAV. These gene complexes encode antigen-
presenting proteins on the surface of a cell to T-lymphocytes. Mutations of 
these gene complexes may lead to autoimmune inflammation that results in 
AAV. Different loci in this gene region were associated with distinct AAV 
subtypes (HLA-DP with PR3-ANCA and GPA, and HLA-DQ with MPO-ANCA 
and MPA). Another genetic association is with PR3-ANCA and the allele 
deficiency of the serpin A1 gene that encodes alpha-1-antitrypsin, which is an 
inhibitor of PR3 (37, 39, 46, 47). These observations underscore the distinct 
genetic background between the two ANCA antigens.      
The genetic findings correlate well with epidemiologic studies. Ethnic 
differences have been observed, with the prevalence of AAV being higher 
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among Europeans than among non-Europeans (30, 31). An American study 
identified that African-Americans with PR3-ANCA-positive AAV were carriers 
of an HLA allelic variant of Caucasian descent rather than a variant of African 
descent (47). Furthermore, patients with positive PR3-ANCA show better 
disease control with rituximab than with cyclophosphamide (CYC), but have a 
higher cardiovascular risk and are more prone to develop relapse after 
transplantation (48-50). Lastly, extrarenal organ manifestation with 
granulomas is more common in PR3-ANCA (51). Additionally, MPO-ANCAs 
are associated with higher treatment resistance, end-stage renal disease 
(ESRD), and death (52, 53). A recent report has also postulated that a rise in 
PR3-ANCA during disease remission is indicative of relapse, particularly in 
patients with severe renal and lung involvement (54). 
These findings imply that AAV consists of distinct disease entities and 
should be classified as MPO- and PR3-ANCA rather than GPA and MPO 
phenotypes when evaluating choice of treatment and conducting clinical trials 
in the future.   
 
Environment  
Environmental agents might elicit AAV in genetically susceptible 
individuals. This hypothesis is strengthened by geographical distribution in 
the occurrence of the disease. The frequency of MPA is 9 times higher in 
rural populations compared to urban areas (24), and GPA has been 
associated with farming and with contact with cattle and pigs (55). Moreover, 
the higher prevalence in the elderly population and no significant gender 
difference implicates cumulative environmental expositional triggers. The 
cyclic pattern and seasonal fluctuations of the occurrence of GPA have been 
associated with risk factors, such as influenza or atopy (20, 34). Furthermore, 
increased nasal carriage of staphylococcus (S.) aureus has been correlated 
with disease relapse, particularly in PR3-ANCA (28, 56). Indeed, nasal 
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carriage of S. aureus occurs in 63% of patients with WG compared to only 
25% in the healthy population (57).  
Several mechanisms have been proposed in the interaction between 
infection and vasculitis. First, an infectious milieu with proinflammatory 
cytokines and other mediators can prime neutrophils to increase the 
expression of PR3 on the cell surface. This might explain the frequent rate of 
relapse in PR3-ANCA AAV (58, 59). Second, pathogenic peptides can 
demonstrate molecular mimicry to the human peptide. During an infection, 
antibodies produced during an infection targeting foreign proteins might 
cross-react with self-peptides and cause autoimmunity. In support of this 
theory are studies that have shown immunization of mice with bacterial 
peptides induced the production of antibodies against human PR3 (60) and 
human lysosome-associated membrane protein-2 (61). Third, S. aureus 
strains that produce superantigens (Toxic Shock Syndrome Toxin-1) 
stimulate lymphocytes and are associated with an increased relapse rates in 
patients with WG (62). Lastly, Toll-like receptors bind infectious agents and 
activate the proinflammatory response. It has been observed that ligation with 
bacterial DNA resulted in ANCA production (56, 63). Chronic nasal 
colonization in patients with GPA might also be facilitated by dysfunctional 
cytokine expression and reduced secretion of Interleukin-8 (IL-8) in the nasal 
epithelium when stimulated by S. aureus (64). Also, these pathogens can 
resist phagocytosis and replicate intracellularly in neutrophil granulocytes 
(65). 
Among other environmental risk factors, low ultraviolet radiation, silica, 
heavy metals, antithyroid and antihypertensive drug allergies, and cocaine 
have been proposed as triggers (66). Exposures to different levels of 
ultraviolet radiation might partly explain the latitudinal gradient of AAV, as 
suggested by some studies. An international ecological study in 2009 
concluded that there was a latitudinal increased incidence of GPA and EGPA, 
but not of MPA (67). Whether this reflects a direct protective effect of ambient 
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ultraviolet radiation or an indirect effect through the effects on vitamin D 
synthesis is unclear. Inhalation of air pollutants, such as silica, has been 
associated with an increase in incidence of AAV, in particular MPO-ANCA 
(68). A recent meta-analysis stated that silica exposure doubled the risk of 
developing AAV (69). This correlation might also explain the increased 
prevalence in rural areas where there are a higher number of industrial 
worksites and more exposure to respirable dust. Both vitamin D deficiency 
and silica have been associated with other autoimmune conditions. The effect 
of tobacco smoking on AAV is not well studied and data are inconsistent (28).  
These findings suggest that although environmental triggers play a key 
role in the pathogenesis of AAV, different genetic backgrounds might also 
determine the responses to these triggers.   
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1.5.  Pathogenesis 
Antineutrophil Cytoplasmic Antibodies  
ANCA were first described in 1982 in patients with segmental necrotising 
glomerulonephritis and clinical symptoms of systemic vasculitis (70). Since 
then, clinical and experimental studies have described the pathogenic role of 
ANCA in GPA, MPA, EGPA, and renal-limited pauci-immune vasculitis, now 
grouped as AAV (71-75). ANCA are present in > 90% of GPA and MPA, and 
approximately 75% of EGPA with GN. These autoantibodies consist 
predominantly of immunoglobulin G. Their presence is specific to AAV and 
titres correlate well with disease activity. PR3-ANCA levels are usually not 
detectable in patients in remission, whereas they are significantly increased in 
active disease. The observed efficacy of immunosuppressive therapy 
targeting B-cells and plasma exchange in AAV is also in support of the 
pathogenicity of ANCA (76-78).  
Animal models showed that when mice were injected with anti-MPO 
immunoglobulin, they developed crescentic glomerulonephritis and systemic 
vasculitis similar to that of humans (79). The pathogenicity of ANCA was 
further described in a case report from 2005 of a newborn that presented with 
pulmonary-renal syndrome after placental transmission of MPO-ANCA (80). 
In vitro studies have shown that ANCA IgG can activate neutrophils that are 
primed by proinflammatory cytokines. Priming causes the cells to release 
MPO and PR3 onto the cell surface and into neutrophil extracellular traps. It 
has been postulated that ANCA binds to these surface autoantigens on 
neutrophils and monocytes, resulting in respiratory bursts, degranulation of 
toxic agents, apoptosis, and necrosis that ultimately result in endothelial 
damage and extracapillary granulomas. These inflammatory agents activate 
the alternative complement pathway C5a, which in turn attracts more 
neutrophils and primes them. This creates an inflammatory loop that amplifies 
the disease process. The neutrophils also extrude extracellular traps 
containing chromatin fibrous material that are decorated with MPO and PR3. 
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These traps might further facilitate the inflammatory response and activate 
the coagulation cascade, resulting in fibrinoid necrosis. Over time, the 
neutrophil-dense necrotic inflammation is replaced with invasion of 
macrophages, monocytes, and T-cells. Breakage of the endothelial cells also 
causes leakage of serum in the interstitial space and activation of epithelial 
cells. This process is observed in the glomeruli as the characteristic crescent 
formation. Activation of fibroblasts will lead to the production of collagen IV 
and the final stage of chronic inflammation, irreversible scarring (76, 77, 81).    
This chain reaction leads to the clinical outcome of small-vessel 
vasculitis with alveolar lung haemorrhage, glomerulonephritis, peripheral 
neuropathy, gastrointestinal ulceration and haemorrhage, and muscle arteritis 
causing myalgia (72).  
Although there is evidence of the aetiopathological effect of ANCA and 
its epitopes in AAV, “natural” ANCA are detectable in serum of healthy 
individuals. These autoantibodies have different epitopes than pathogenic 
ANCA, and have both lower titres and lower affinity to neutrophils. Epitope 
diversity may also be a possible explanation for patients with AAV, who are 
ANCA-negative, according to routine enzyme-linked immunosorbent assays 
(ELISA). It is hypothesised that exogenous stimuli, such as infection, atopy, 
or silica can alter epitope specificity, and cause a pathogenic transformation 
(82, 83).  
 
Complement factors 
Until recently the role of complement factors had in the pathogenesis of 
AAV, has been incompletely described, partly due to their absence in kidney 
biopsies (1). However, experimental and biopsy data have recently 
illuminated their key role, particularly in the alternative pathway in AAV (77). 
Complement factors have been observed in both serum (84) and urine (85) in 
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patients with AAV. Furthermore, groups have also discovered that inhibiting 
complement C5 in the complement pathway protected against glomerular 
damage (86, 87). C5a acts as a chemoattractant and primer of neutrophils. 
Activated neutrophils secrete mediators that in turn amplify the complement 
pathway, causing a positive feedback loop. Attenuation of GN by blocking 
factor B and the presence of properdin in biopsies of patients with AAV 
indicate that the alternative pathway is pivotal in the pathogenesis of AAV 
(88). Low baseline serum complement C3 is also associated with an 
increased risk of ESRD and death (89, 90). 
 
B-cell activating factor 
B-cell activating factor promotes B-cell survival and immunoglobulin 
synthesis. Autoreactive B-cells are particularly dependent on these factors for 
maturation. Elevated levels of this factor have been shown in rheumatologic 
diseases, including WG, when compared to healthy controls (91, 92). 
Researchers are currently investigating therapeutic agents (belimumab and 
blisibimod) targeting this factor (93).  
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1.6. Clinical Characteristics  
Organ damage 
AAV is pathologically characterised by an inflammatory reaction in the 
blood vessels with fibrinoid necrosis and granulomatous lesions. Despite 
having similar pathophysiology, there are certain clinical differences between 
GPA, MPA, and EGPA. Upper respiratory manifestations are more common 
in GPA than MPA. Granulomas are less frequent on histologic examination of 
MPA (94, 95). In addition to granulomas, EGPA is characterised by the 
presence of asthma and hypereosinophilia, and less frequently, circulating 
ANCAs (96).  
Patients with AAV usually experience prodromal “flu-like” symptoms 
with fever, headaches, anorexia, malaise, weight loss, and myalgia or 
arthralgia. The prodromal symptoms might last for several weeks or months. 
Other presentations might be local vasculitis with as a skin rash and tender 
nodules, scleritis, bloody rhinitis, or arthritis. Ear, nose, and throat (ENT) 
involvement such as hearing loss, otalgia, recurrent sinusitis and otitis media, 
saddle nose, or nasal crusting may be the initial clinical manifestation. The 
upper respiratory tract is involved in most patients with GPA (70-100%), but 
only in 35% of patients with MPA (1, 97). In a recent report among 414 
patients enrolled in clinical trials, 45% presented with ENT involvement (77% 
of patients with GPA and only 23% of patients with MPA) (98). 
Lung affection with alveolar haemorrhage and GN are hallmark lesions 
of AAV and important causes of morbidity and mortality. GN occurs in about 
70-80% of all cases (53, 98, 99), ranging between 11-77% in GPA, 79-100% 
in MPA, and 12-67% in EGPA (100-103). The occurrence of alveolar 
haemorrhage is observed to be 7-45% in GPA, 10-30% in MPA, whereas it is 
rare in EGPA (104). Hirayama and colleagues reported in their study of 1147 
Japanese patients with ANCA-GN, most of them with MPO-ANCA positive, 
that 52% had lung involvement of which 15% had severe lung haemorrhage 
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(105). About 50% of patients have cutaneous manifestations, such as rash 
and tender nodules. Disease manifestations of the nervous system and the 
eyes are also common (2, 106, 107). 
 
Table 2. Clinical manifestations in AAV  
Organ Clinical manifestation 
General Fever, malaise, fatigue, anorexia, weight loss, neck ache, 
headache, polymyalgia, polyarthralgia 
Cardiovascular Pericarditis, pericardial effusion, occlusive vascular disease, 
cardiomyopathy, congestive heart failure 
ENT Hearing loss, otalgia, otitis media, nasal crusting, epistaxis, 
mucosal inflammation, nasal bridge collapse, recurrent 
sinusitis, mouth ulcers 
Eye Scleritis, episcleritis, keratitis, uveitis, retinal changes 
Gastrointestinal Mesenteric vasculitis, bowl ischaemia, peritonitis 
Kidney Haematuria, proteinuria, cellular casts in urine cytology, 
rapid renal impairment 
Nervous 
system 
Cranial nerve palsies, sensory peripheral neuropathy, 
mononeuritis multiplex, seizures, meningitis 
Respiratory Tracheal stenosis, cough, stridor, wheezing, dyspnoea, 
haemoptysis, lung nodules, pleuritis and effusion, 
pulmonary haemorrhage, respiratory failure 
Skin Tender nodules, livedo reticularis, leucocytoclastic angiitis, 
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digital infarcts, cutaneous ulcers and purpura, genital ulcers 
 
 
Figure 1. Organ manifestations in ANCA-associated vasculitis. Reproduced from [Diagnosis and management of ANCA 
associated vasculitis, Annelies Berden et al., vol.nr: 344, page numbers: e26, copyright notice year: 2012] with permission 





The signs and symptoms of AAV might vary and therefore delay the 
diagnosis for months, resulting in irreversible organ damage. Thus, the 
clinician must be vigilant and consider testing patients with unexplained 
chronic inflammatory disease, particularly in the airways and the kidneys. 
Kidney affection typically presents with haematuria and proteinuria, but 
patients might not perceive it until symptoms of uraemia are present. Early 
urine dipstick testing and microscopic urine sediment analysis will reveal 
erythrocytes, granular casts, and erythrocyte casts compatible with 
glomerulonephritis. A blood test should also be performed in the initial 
evaluation, which might reveal increased serum creatinine, elevated C-
reactive protein and erythrocyte sedimentation rate, and decreased 
leucocytes and platelets. Although erythrocyte sedimentation rate and C-
reactive protein are non-specific markers of inflammation, they have high 
sensitivity for active vasculitis and are helpful in ruling out the condition (108). 
A normochromic-normocytic anaemia may also be indicative of a systemic 
inflammatory disease (1, 2, 97).  
Patients with antibiotic-refractory cough and haemoptysis should have 
a chest X-ray to reveal lung nodules/granulomas or infiltrates. Cases with 
unexplained conjunctivitis, retroorbital mass, or skin vasculitis with general 
symptoms should also be targeted for testing (97). Differential diagnoses 
such as infection, malignancy, or drug-induced vasculitis are also important to 
rule out (109).    
The Birmingham Vasculitis Activity Score (BVAS) is a validated 
instrument for assessing disease activity in systemic vasculitis, especially 
GPA. It contains a list of 66 manifestations of vasculitis with nine organ-
specific symptoms. The sum of the score from all organs reflects the disease 
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activity and severity, and ranges from 0-68. The BVAS can be used in new, 
persistent, or relapsed disease (110, 111).  
 
Serology 
With the introduction of the indirect immunofluorescence (IIF), ANCA 
became a sensitive serologic marker for AAV. In GPA, ANCA produce a 
diffuse granular cytoplasmic staining pattern in ethanol-fixed neutrophils (C-
ANCA) (112), whereas it produce a perinuclear-staining pattern in MPA and 
EGPA (P-ANCA) (113). The primary target antigens for P- and C-ANCA were 
identified as MPO and PR3, respectively. When preparing with ethanol, MPO 
would dissolve from cytoplasmic granules and attach to the nucleus, resulting 
in a perinuclear-staining pattern, whereas PR3 would not dissolve and 
therefore yield a cytoplasmic staining pattern. The ELISA test, using purified 
MPO and PR3 for ANCA detection, was developed and made commercially 
available in 1990 (72, 114).  
Most laboratories use the IIF as a screening method to identify ANCA, 
and if positive, then they perform a confirmatory ELISA test (115). IIF has 
higher sensitivity, but ELISA is more specific. The combined sensitivity and 
specificity of these two tests have been estimated to be 82% and 99%, 
respectively (116, 117). According to four large international randomised 
trials, ANCAs are positive in 90-95% of patients with active GPA or MPA (78, 
118-120). In GPA, PR3-ANCAs are detected in 40-90% of patients, whereas 
MPO-ANCAs are identified in less than 10% of cases. MPO-ANCAs are 
detected in 65-90% of patients with MPA and in 30-40% of patients with 
EGPA (121).  
In summary, GPA has a classic cytoplasmic pattern in IIF and is 
associated with PR3-ANCA, while MPO-ANCA and the perinuclear pattern on 
IIF is more common in MPA and EGPA.  
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Patients with symptoms of AAV should be referred to the nearest 
specialist for care, especially when presenting with organ failure. An ANCA 
assay can be requested in all hospitals and is a tool for diagnosis and a 
marker of disease activity. ANCA serology helps to distinguish between 
disease entities, and predict response to therapy and disease control (2, 109, 
122). Nevertheless, the result must be evaluated based on the clinical 
findings. A negative test does not exclude the diagnosis, as some patients 
have an ANCA-negative disease. Possible explanations for a negative test 
might be epitope diversity or ANCA specificity to other antigens (e.g. anti-
elastase and cathepsin G). One study has shown that among ANCA-negative 
cases, a blood serum factor binds to specific MPO-epitopes-ANCA and 
prevents them from being detected by routine tests. These immunoglobulins 
were detected only after they were purified (123-125). If the clinical suspicion 
is high, despite a negative ANCA test, the assay should be repeated after a 
few weeks. One must also keep in mind that ANCA are not specific for AAV 
as it is detected in other inflammatory conditions, such as inflammatory bowel 
disease, infection, rheumatoid arthritis, connective tissue disease, and 
secondary to drug reactions (126). Thus, it is not advised to use it as a 
screening tool without a clear indication. On the other hand, a high ANCA titre 
combined with multiorgan affection is indicative of AAV (127).  
In Table 3, McLaren and colleagues have proposed a list of clinical 
syndromes associated with systemic vasculitis where the ANCA assay is 
recommended (121, 128). 
Table 3. Clinical indications for ANCA testing  
Chronic necrotising disease of the upper airways  
Cavitating pulmonary nodules 
Suspected Churg-Strauss syndrome 
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Pulmonary-renal syndrome, pulmonary haemorrhage 
Subglottic stenosis 
Refractory sinusitis or otitis  
Rapidly progressive glomerulonephritis 
Cutaneous vasculitis accompanied by systemic symptoms 
Mononeuritis multiplex or peripheral neuropathy 
 
Novel markers. A new and promising diagnostic biomarker of AAV, is 
anti-pentraxin-3 autoantibodies. Pentraxin 3 has similarities with PR3 and 
MPO autoantigens, and is stored in neutrophil granules. A study showed that 
these autoantibodies were present in 56 of 150 AAV patients compared to 
only 12 out of 227 patients with IgA nephropathy. Also, it had a distinct 
staining pattern on IIF compared to classic C-ANCA and P-ANCA. Higher 
levels of autoantibodies were also detected during active disease than under 
quiescence (129). Lysosome-associated membrane protein-2 antibodies are 
also potential biomarkers that are present during active disease and not 
detectable during remission. Interestingly, these autoantibodies have also 
been found in patients, who are ANCA-negative (130). Elevated complement 
factors have been observed in the blood and urine during active disease 
compared with that during remission. Activated complement factor B was also 
inversely correlated with the percentage of normal glomeruli in the biopsy (84, 
85). Standardised assays need to be developed and validated in large 
cohorts before these tests can be implemented in routine care.  
Renal biopsy 
A biopsy is the gold standard in the diagnosis of ANCA-GN. The 
inflammation in the glomerular capillary can cause disruptions of the 
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glomerular basal membrane. The influx of inflammatory mediators and fibrin 
causes fibrinoid necrosis and causes leukocytes to produce cellular crescent 
formation in the Bowman’s space. The lesions might be acute with 
cellular/fibrocellular crescents or fibrous in more developed stages, with the 
invasion of collagen-producing fibroblasts. The proportion of affected 
glomeruli might vary from focal and segmental lesions to diffuse and global 
injury. Interstitial inflammation can also be apparent with nephritis, tubulitis, 
and tubular atrophy. The GN might also be accompanied by granulomas and 
interstitial vasculitis (131-133).  
The crescentic and necrotising inflammation in light microscopy is 
indicative of a rapid and progressive GN. In addition to ANCA-GN, possible 
differential diagnoses include immune complex-mediated diseases (e.g. lupus 
nephritis, anti-glomerular membrane disease, IgA nephritis and postinfectious 
GN). Immunofluorescence staining of the biopsy is the next step to 
differentiate these conditions. In ANCA-GN, there is usually a low level of 
immunoglobulin pattern, a so-called “pauci-immune” appearance, 
characterised by < 2 on a scale from 0 to 4 (76). Conversely, a granular 
staining pattern is suggestive of immune complex-mediated disease, whereas 
a linear immunoglobulin G staining pattern indicates anti-glomerular 
membrane disease.  
The renal biopsy has been reported to influence and guide therapy 
decisions in 82% of all cases (134). The rate of biopsy might vary, but 
Scandinavian groups have documented a biopsy rate ranging from 68 to 87% 
in patients with ANCA-GN (16, 131). 
Complications of renal biopsy are rare. Macroscopic haematuria and 
need for erythrocyte transfusion occurs in about 2-3 % and 1% of all biopsies, 
respectively. Perinephric haematoma is more prevalent and appears in 12% 
in all cases, but only approximately 0.5% of all patients are in need of 
angiographic intervention to stop the bleeding. Risk of bleeding is associated 
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with older age, systolic blood pressure, poor renal function, and small hospital 
size where the procedure was performed. Lastly, in a large meta-analysis, 
only two deaths were observed following 8971 biopsies (135, 136).  
Although renal biopsy is a relatively safe procedure, the need for this 
practice in patients, who are ANCA-positive, with typical clinical symptoms, is 
debatable. Another controversy with tissue sampling is its utility as a 
longitudinal prognostic marker; The procedures are invasive and not 
desirable for repeated assessments of disease control (108).   
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1.8. Treatment and adverse effects 
The aim of therapy in ANCA-GN is the induction of remission and 
resolution of symptoms, such as haematuria, proteinuria, and improved 
serum creatinine. Response to treatment varies; some patients experience 
refractory disease with declining renal function despite high doses of 
immunosuppression, whereas other patients experience complete remission, 
with or without any relapses. Judicious caretaking and tailoring therapy is 
prudent for optimal outcome.    
Since autoantibodies play a major role in the pathogenesis of AAV, B-cell 
depletion is an important target in therapy. In the early 1950s and 1960s, 
steroid monotherapy was introduced as a treatment for AAV. Prior to this, no 
standardised therapy was described. Untreated patients had a poor outcome 
and over 90% died after two years. Most patients died of renal failure and 
respiratory dysfunction (137). Since the 1970s, the addition of CYC led to a 
dramatic improvement in prognosis. With immunosuppression, survival rate 
rose to 90% during the first year after diagnosis and 75% achieved complete 
remission. However, CYC is associated with an increased risk of infections 
and malignancy. During recent years, several landmark clinical trials aiming 
at reducing the exposure to CYC and investigate alternative and more 




Glucocorticoids are the cornerstone in therapy and usually administered 
as intravenous (IV) methylprednisolone 1 g for three consecutive days. 
Thereafter treatment with oral prednisone of 1 mg/kg up to 80 mg per day for 
4 weeks follows, before gradually tapering, e.g. 10% every 1 to 2 weeks, over 
3-5 months (139). Long-term steroid use is associated with adverse effects, 
especially infections, osteoporosis, hypertension, cataracts, skin atrophy, 
gastrointestinal bleeding, cardiovascular disease, and diabetes. Although 
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some suggest discontinuing low-dose steroids after 6 months, optimal 
duration of therapy remains controversial (140-146).  
 
CYC or rituximab combined with steroids is recommended as first line 
treatment in inducing remission in patients with severe AAV. In non-organ-
threatening disease, methotrexate (118, 147) or mycophenolate mofetil (148) 
can be considered. Methotrexate is equally efficient as CYC in remission 
induction, but less effective in preventing relapses (149). Plasma exchange is 
considered as a rescue therapy in patients presenting with lung haemorrhage 
and/or serum creatinine > 500 μmol/L (78, 139). Although this procedure 
improves renal survival, the overall mortality is unchanged. Long-term benefit 
of plasma exchange needs to be studied further (150). In a clinical setting, 
patients with severe organ failure receive both plasma exchange and IV 
glucocorticoids simultaneously (151).  
  
CYC is a cytotoxic agent that inhibits DNA replication by alkylating 
guanidine nucleotides (152). It is administered as either pulse IV (15 mg/kg 
every 14 days for 1 month, then every 3 weeks) or as continuous daily 
treatment by oral route, usually at doses of 2 mg/kg. The dose may be 
adjusted depending on leukocyte count, age, and renal function. The duration 
of treatment depends on patient response, but is recommended from 3 to 6 
months. Although both routes are equally effective in achieving remission, the 
cumulative dose of CYC is higher with oral administration and is associated 
with a lower rate of relapses (119, 153). However, the IV route is associated 
with fewer bladder-related adverse effects and favoured over oral in the latest 
therapy guidelines (139). CYC is associated with severe adverse effects, 
such as haemorrhagic cystitis, infertility, leucopoenia or neutropaenia, 
alopecia, bone marrow toxicity and malignancy (97, 119, 138, 154, 155). 
 
Rituximab is an anti-CD20 monoclonal antibody that targets B-cells and 
induces apoptosis and depletion of the cell population for up to 12 months 
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(156). It has been proven non-inferior to CYC in two randomised clinical trials 
in remission induction, combined with steroids. In addition, rituximab had 
better disease control, particularly in PR3-ANCA AAV (157, 158). In these 
studies, patients received infusions of 375 mg/m2 once a week for 4 weeks. 
The frequency of adverse effects, such as infection, was comparable with 
rituximab and CYC. Owing to the high cost, rituximab should be considered in 
patients who plan to get pregnant, or have relapsing/refractory disease. 
Vigilant monitoring with blood tests is advised since rituximab is associated 
with hypogammaglobulinemia and opportunistic infections (156, 159, 160).      
 
Maintenance therapy 
The optimal duration of maintenance therapy remains unknown. It is 
guided by both the clinical and the serologic response to treatment. 
Consensus guidelines recommend continued treatment for at least 24 
months. Prolonged maintenance therapy was associated with fewer relapses 
as opposed to early cessation (109, 139, 146). Thus, the duration of therapy 
should be tailored based on a global assessment of the patient (161, 162). 
Routine examination should be conducted every 1 to 3 months with clinical 
assessment, blood, and urine analyses. Longitudinal ANCA measurements 
might help to identify patients at risk of disease flares, who could benefit from 
intensifying monitoring. However, persistent ANCA or an altering titre is an 
insufficient reason to change therapy (54, 163, 164).  
 
The therapeutic armamentarium includes azathioprine (120, 165), 
methotrexate (166, 167), rituximab (168, 169), mycophenolate mofetil (170), 
and leflunomide (171). Azathioprine (2 mg/kg/day) and methotrexate (20-25 
mg/kg/week) are equally effective, but azathioprine is preferred in patients 
with renal insufficiency (166). Mycophenolate mofetil (2 g/day) was 
associated with more frequent relapses compared to azathioprine, and should 
be restricted to patients who are intolerant of azathioprine (170). Leflunomide 
(20 mg/day) is an alternative to azathioprine and methotrexate, but its role in 
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therapy of AAV needs to be elucidated further (171). The role of rituximab in 
maintenance therapy is under investigation and lacks consensus. Choosing 
the optimal relapse-preventing protocol after induction infusion poses a 
challenge and needs to be refined. Current protocols recommend rituximab-
based regimens for refractory or relapsing disease, particularly in PR3-ANCA 
AAV (139, 169, 172-175).  
Prophylactic co-trimoxazole in high doses (320/1600 mg/day), in addition 
to standard therapy might further reduce the risk of relapse (176). More 
importantly, low-dose co-trimoxazole is recommended to prevent 
Pneumocystis jiroveci pneumonia (109).  
 
Transplantation 
Patients in a period of quiescence can be referred for a renal 
transplantation. Both patient and renal survival was better in AAV-grafts than 
in a matched non-diabetes cohort (177). Furthermore, graft and patient 
survival have been estimated to be 100% after 1 year, and 79% and 67% 
after 10 years (178). A recent Dutch study showed that 11 of 110 patients 
with ANCA-GN relapsed within the first 5 years after transplantation. Disease 
recurrence was independently associated with allograft loss (179).    
 
Novel agents  
Currently, the B-cell activating factor inhibitors belimumab and blisibimod 
are under investigation in clinical trials. Compared to rituximab, these drugs 
are more selective and have more favourable safety profiles (93, 109). 
Preliminary results from a recent clinical trial showed that the addition of 
CCX16 (a C5aR inhibitor) to standard therapy, successfully replaced steroids 
in remission induction of AAV (180). Trials with etanercept, a tumour necrosis 
factor (TNF) alpha inhibitor, have been unsuccessful and associated with 
increased risk of infection and cancer (181).   
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1.9. Prognosis and Outcome 
Patient Outcome 
Although the clinical outcome has improved over time, mortality and 
morbidity remain high. The survival rate varies with study design, definition of 
end-points, age distribution, disease severity, and the length of follow-up. 
Compared to the general population, patients with AAV have an increased 
mortality rate with an estimated standardised mortality ratio (SMR) ranging 
from 1.6-3.6 (3, 182-184). In tables 4 and 5, results from studies offering data 
on patient survival, renal survival and SMR in patients with AAV are 
summarized. 
In a Norwegian cohort of patients with WG, SMR was calculated to be 
3.8 (107), which is better than what was described in an American cohort of 
patients with WG (SMR 4.6) (185).  
Survival within the first year after diagnosis has been reported between 
71% and 99% and between 66% and 90% during 5 years of follow-up (3, 53, 
106, 107, 182-184, 186-192). In a follow-up study of patients with AAV 
enrolled in clinical trials, a 1- and 5-year cumulative survival of 88% and 78% 
was reported, respectively (3). Five-year patient survival for AAV phenotypes 
ranged from 74-91% in GPA, 45-76% in MPA, and 60-97% in EGPA, 
respectively (193). One- and 5-year survival rates have been reported to be 
more favourable for patients with PR3-ANCA-positive disease (87% and 
72%) compared to patients with MPO-ANCA-positive disease (86% and 66%) 
(53).  
Patients with AAV who present with severe disease have a poor 
prognosis. In a retrospective cohort study of 36 PR3-ANCA and 17 MPO-
ANCA positive cases, patients with lung haemorrhage had 83% and 58% 
survival rates were seen at 3 and 49 months of follow-up, respectively (194). 
In these patients, 98% also had renal vasculitis and 53% a need for RRT. In 
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another study, Hirayama et al. (1088 patients with MPO-ANCA and 114 
patients with PR3-ANCA) described a 5-year survival rate of 42% in patients 
with AAV with lung haemorrhage compared to 73% in those without lung 
involvement (105). In a French study, patients admitted to an intensive care 
unit in northern France due to an acute manifestation of small-vessel 
vasculitis, which included AAV and anti-glomerular basement membrane 
disease, had a 90-day mortality rate of 18%. The primary cause for admission 
was respiratory failure, and most of the deaths were related to disease flare 
and infection (195). The 1-year survival rate in patients with ESRD is reported 
to be in the range 64-83%, and 28% were alive after 5 years of follow-up 
(196).  
During the first year, therapy-related adverse events, such as infections 
and active vasculitis, were the primary causes of deaths (3, 183, 187, 197, 
198). Cardiovascular diseases and neoplasms are common causes of deaths 
after the first year of follow-up. In long-term follow-up of patients enrolled in 
clinical trials, disease-related renal dysfunction (reduced eGFR, hypertension, 
and proteinuria), otolaryngological damage (hearing loss, nasal crusting), and 
treatment-related damages (hypertension, osteoporosis, diabetes, and 
malignancy) increased over time (3, 141, 199). 
 
Renal Outcome 
ESRD occurs in 14-28% of all patients with AAV (53, 184, 196, 199). In 
a Norwegian cohort of patients with GPA, 10 out of 53 patients developed 
ESRD, with 1-, 5-, and 10-year renal survival estimated to be 93%, 86%, and 
77%, respectively (186). In comparison, a recent retrospective American 
study showed an overall renal survival of 67%. In this study, the cumulative 
renal survival at 1- and 5-years was estimated to be 75% and 54%, 
respectively (191). Therefore, ESRD remains a major concern in this patient 
group. Patients with ESRD are more susceptible to severe infection-related 
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death (20% versus 8%) than in non-AAV controls (200). Older patients, in 
particular, have poorer renal function and are more susceptible to the toxic 
effects of treatment, with accelerated progression to ESRD. Among elderly 
patients > 75 years with GPA and MPA, a multicentre study reported 1-year 
and overall renal survival to be 75% and 72%, respectively (189). However, a 
similar trend has also been described in paediatric cohorts. In a nationwide 
study of young patients with AAV younger than 18 years, progression to 
ESRD was 74% and 70% after 1- and 5-years of follow-up, respectively. 
Nonetheless, the mortality rate was only 6% during follow-up, which is less 
severe compared to that in adult cohorts (201).  
It has been suggested that patients with MPO-ANCA have a higher risk 
of developing ESRD than patients with PR3-ANCA (52, 53, 101, 202), but 
ANCA specificity had no significant prognostic value in a recent study by 
Rhee et al. (191). In addition, in patients with AAV and ESRD, MPA 
phenotype might indicate poorer renal allograft survival and higher mortality 
rate (203). 
Patients with severe renal dysfunction at diagnosis may not respond to 
conventional treatment and are at risk of developing ESRD and/or death. In a 
recent clinical trial, investigators included 137 patients with newly diagnosed 
AAV and a serum creatinine > 500 μmol/L. Adjuvant IV methylprednisolone 
was compared to plasma exchange, in addition to oral CYC and 
corticosteroids. During a median follow-up of 4 years, 86 (63%) developed 
the composite end-point of ESRD and/or death. Thirty-three developed ESRD 
in the steroid group compared to 23 in the plasma exchange group (p = 0.08). 
The most common cause of death was severe infection (150).  
Patients on RRT have a median survival rate of 5 years. Cumulative 
survival rates at 3 months, 1, 3, and 5 years of follow-up are estimated to 
96%, 85%, 68%, and 53%, respectively. Cardiovascular and infections were 
the most common causes of death in patients and AAV on chronic dialysis. In 
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one study, 45 of 425 patients with AAV who were in need of RRT at diagnosis 
regained their renal function, and 19 remained dialysis-free during the study 
period (200). Aasarød and co-workers reported in their study that almost 50% 
of patients who were on dialysis at diagnosis benefited from therapy and 
regained their renal function (107). These findings emphasise the Kidney 
Disease Improving Global Outcome guidelines statement that 
immunosuppressive treatment should be continued for at least 3 months in 
patients with ESRD.  
 
Relapse 
Despite numerous trials and advances in treatment, AAV remains an 
incurable disease, and over time, 50% experience relapse (97, 101, 107, 
161). Among patients with AAV enrolled in clinical trials, 38% relapsed during 
1804 patient-years at risk. PR3-ANCA and cardiovascular involvement 
increased the risk of relapse, while an initial serum creatinine level > 200 
μmol/L was associated with lower relapse rate (161). ESRD and death might 
act as competing risk factors for relapse, and patients with better renal 
function might live long enough to develop relapses. Also, uraemia can cause 
dysfunction in the immune system that might hinder a relapse (161).  
In a retrospective cohort study from the United States, 35% of patients 
with AAV relapsed. In this study, interestingly, no temporal improvement in 
renal relapse rate was observed. Also, duration of CYC or ANCA subtype had 
no prognostic impact on relapse (191). This is in contrast to previous studies 
(52, 188, 202, 204), which have shown a 2-fold increased risk of relapse in 
patients with positive PR3-ANCA compared to patients with MPO-ANCA. In 
recent Chinese cohorts of patients with AAV, patients with PR3-ANCA had a 
30% increased risk of relapse compared to patients who were MPO-ANCA-
positive (205, 206). In young patients, a paediatric cohort study of patients 
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with AAV showed that 43% relapsed after a median follow-up period of 5 
years (201).  
In a randomised clinical trial conducted by Sanders and colleagues, 
with patients with positive C-ANCA in quiescence, extended azathioprine 
maintenance therapy had a limited effect on relapse-free survival compared 
to standard therapy. Moreover, positive C-ANCA serology at remission was 
not associated with a large number of cases with relapses (163). 
 
Risk factors 
Older age, dialysis-dependency, low serum albumin, higher serum 
creatinine, lower BVAS score, and lung involvement at baseline are 
associated with higher mortality. Poor renal function at diagnosis and severe 
scarring (global sclerosis) of the glomeruli has been associated with ESRD 
(3, 106, 107, 133, 186, 188, 189, 191, 207, 208). Conversely, PR3-ANCA 
subtype is associated with better renal survival (53, 202). The results are 
conflicting regarding differences in mortality between ANCA specificity, and 
recent studies have not found any significant differences (3, 52, 53, 202). 
Novel discoveries in genetic differences between PR3-ANCA and MPO-
ANCA with distinct treatment response and outcome might indicate a need for 
a new ANCA type classification. This might simplify future clinical trials and 
guide therapy (37, 48, 53, 202, 203, 209, 210). Also mentioned previously, 
serum C3 is an independent predictor of long-term renal and patient survival 
(89, 90). 
 
Lionaki and colleagues described in their retrospective study of AAV 
that patients who progressed to ESRD received shorter duration of 
immunosuppression with CYC, compared to patients who did not develop 
ESRD (52). Upper respiratory involvement is associated with better patient 
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outcome (98, 183, 211). Studies have also demonstrated an improved 
prognosis in patients with AAV diagnosed in recent times, compared to that of 
previous decades. More awareness of this disease entity and earlier 
diagnosis with less pronounced kidney failure has been postulated as an 
important contributor to this trend (182, 183, 188, 192, 208). 
 
Table 4. Cohort studies on patient and renal survival in AAV 
Authors 
(reference) 
Year No. of 
patients 




Aasarod (107) 2000 108 WG 91%*/75% 93%*/74% 
Reinhold-Keller 
(106) 
2000 155 WG NR 99%/NR 
Koldingsnes 
(186) 
2002 56 WG 93%/86% 93%/79% 
Slot (187) 2003 85 PR3-GN NR 80%/73% 
Booth (184) 2003 246 AAV-GN NR 84%/76% 
Eriksson (182) 2009 95 WG/MPA 94%/89%* 93%/84%* 
Takala (183) 2010 492 WG NR 83%/74% 
Flossmann (3) 2011 535 AAV NR 88%/78% 
Hilhorst (188) 2013 181 AAV-GN 67%/54% 77%/66% 
Mohammad (53) 2014 201 AAV 84%/77% 86%/69% 
Andreiana (190) 2015 75 AAV 93%/64% 88%/67% 
Weinera (189) 2015 151 AAV 75%/NR 71%/NR 
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Wallace (192) 2016 465 GPA NR 91%/78%* 
Rhee (191) 2016 554 AAV-GN 75%/54% 91%/72% 
*Calculated estimate; aElderly population ≥ 75 years 
Table 5. Standardised mortality ratios (SMR) in patients with AAV  
Authors (reference) Year N SMR 95% CI Predictors of outcome 
Aasarod (107) 2000 108 3.8 2.6-5.6 Age at inclusion, low serum 
albumin 
Booth (184) 2003 246 3.6 1.6-7.1 Age > 60 years, ESRD, initial 
creatinine > 200 umol/L, and 
sepsis 
Lane (212) 2005 99 4.8 2.9-6.6 Age > 65 years 
Eriksson (182) 
 aCohort 1 
 bCohort 2 






Age, creatinine, ESRD, 
relapse, diagnosis before 
1997 
Takala (183) 2010 492 3.4 3.0-3.9 Older age and elevated 
creatinine at diagnosis 
Holle (208) 2011 445 1.6 1.1-2.1  
Flossmann (3) 2011 535 2.6 2.2-3.1 eGFR < 15 ml/min per 1.73 
m2, older age, high BVAS 
score, low Hb and higher 
white cells count 
Schirmer (213) 2016 144 1.4 0.9-2.1 Fibrosing interstitial lung 
disease, age at diagnosis, 




   
aEarly cohort; bLate cohort; c5-year survival ratio  
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1.10. Malignancy 
The association between immunosuppression and cancer has been 
known for several decades (214). Accordingly, several researchers have 
investigated the risk of cancer in patients with AAV undergoing 
immunosuppressive therapy. A brief summary of studies and results on the 
subject are presented in table 6. 
There is a well-documented correlation between cancer and chronic 
systemic autoimmune diseases, such as rheumatoid arthritis (215), 
inflammatory bowel disease (216, 217), celiac disease (218), systemic lupus 
erythematosus (219), and sarcoidosis (220). Studies on patients who were 
treated with CYC for other malignant diseases had a dose-dependent 
increased risk of bladder and haematologic cancers (221, 222). Furthermore, 
there is a well-known association between immunosuppressive therapy and 
the occurrence of skin cancer in renal recipients (223). Thus, one of the 
objectives of the international renal research community was to investigate 
how to refine therapy to reduce the risk of malignancy.  
Possible pathogenic pathways of malignancy in autoimmune diseases 
include putative interactions with treatment drugs, viral exposure, and 
traditional lifestyle risk factors (224, 225). The alkylating properties of CYC 
may cause mutations in the p53 tumour suppressor gene, and increase the 
risk of malignancies. Haemorrhagic cystitis, an adverse effect of CYC, was 
previously reported to precede bladder cancer, but this trend has not been 
verified in newer data. Hence, it is probably not a good marker for intensifying 
cancer surveillance. However, patients who have been exposed to CYC and 
later develop haematuria should be referred for a prompt cystoscopy (155).  
The toxic and mutagenic properties attributed to immunosuppressive 
therapy, especially CYC, motivated researchers to find alternative treatment 
regimens (97, 138). The increased risk was most pronounced for urothelial 
carcinoma, squamous cell skin cancer, leukaemia, and lymphoma. The 
 48 
excess risk depends on both the intensity and the duration of therapy. The 
bladder is particularly exposed to CYC toxicity due to renal excretion of the 
metabolites. There is a 7- to 11-fold increase in the risk of bladder cancer for 
at least a year after exposure to CYC (101, 155). According to Knight et al., 
the risk of bladder cancer doubled for every 10-gram increment in cumulative 
CYC dose and the risk was particularly high when cumulative doses 
exceeded 25 grams (155). In another study, by Faurschou et al., the risk for 
malignancies only increased in patients treated with high cumulative doses 
exceeding 36 grams of CYC. Thirty-six grams corresponded to 100 mg CYC 
per day for at least a year. There was also a long latency, up to 20 years, in 
the occurrence of malignancy after cessation of treatment (226, 227).  
The introduction of sequential regimens, alternative 
immunosuppressive drugs, and lessons from landmark clinical trials heralded 
a new CYC sparing era. Compared to oral CYC, IV has less than 50% of the 
cumulative dose, and is less harmful for the urinary bladder. The decline in 
bladder cancer might reflect this trend; both Hoffman (97) and Talar-Williams 
(138) found a 30-fold increased risk in their American cohort; in contrast, 
there is only a 1- to 5-fold increased risk in recent studies. This might be due 
to the fact that 35% of all patients in this cohort received > 100 g CYC, while it 
was only 8% in a recent Danish cohort (226).  
Early studies (Table 6) reflect older treatment regimens and might not 
correlate to present therapy related malignancies. Recent studies show a 
non-significant increase in cancer when excluding non-melanoma skin cancer 
(NMSC), which was the most prevalent type of cancer (228, 229). NMSC 
seems to be a major contributor to the reported standardised incidence ratio 
(SIR) for cancer, while the more severe bladder and haematologic cancers 
were rarer. NMSCs are the most common malignancy in transplant recipients. 
Azathioprine in particular is associated with sensitising the skin to the 
mutagenic effect of ultraviolet radiation. Ultraviolet radiation results in 
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decreased epidermal Langerhans cells (antigen presenting cells), which 
ultimately lead to dysfunctional local immunosurveillance (230, 231).  
Cancer plays a major role in the morbidity of this patient group, but is a 
less prominent cause for mortality. Nonetheless, standard long-term care 
should include comprehensive haematologic, dermatologic, and urologic 
examinations.  The potential risk of cancer with use of other therapeutic 
agents in AAV is still unclear and remains to be explored.  
 
Table 6. A selection of studies on cancer incidence in AAV 
Author (reference) Westman 
(101) 
Knight (232) Faurshou 
(226)  
Holle (208)  Heijl (228) Rahmattulla 
(229)  
Country Sweden Sweden Denmark Germany Europe  Netherlands 
Study design Monocentre Nationwide Nationwide Monocentre Multicentre Monocentre 
AAV phenotypes studied GPA/MPA GPA GPA GPA GPA/MPA PGA/MPA 
Follow-up period 1971-93 1969-1994 1973-1999 1966-2005 1995-2007 1991-2013 
Patients (n) 123 1065 293 445 535 138 
Mean/median obs. period 
(years) 
4.6 NR 6.0 5.9 5.0 8.0 
Cum. obs. period (person-
years) 
944 5708 2121 2572 2650 1339 
Mean/median age (years) 61.8 NR 59.0 51.7 57.7 59.3 

























Leukaemia (n) and SIR (95% 
CI) 




3* 2 (3.25, 
0.4-11.8) 
 




















*Leukaemia and lymphoma combined 
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1.11. A Histopathologic Classification Model 
In 2010, an international vasculitis group consisting of nephrologists 
and pathologists proposed a histologic classification model for ANCA-GN. 
The histopathological lesions in the glomeruli were divided into four classes: 
focal, crescentic, mixed, and sclerotic. The classification depends on the 
predominant change (≥ 50%) of the glomeruli. The focal class depends on ≥ 
50% normal glomeruli, whereas the crescentic and sclerotic class have a 
predominance of cellular crescents and globally sclerotic glomeruli (≥ 50%). 
The biopsy is classified as mixed when no predominant lesions are present. 
The classification model was validated in 100 biopsies of patients with AAV, 
who were included in clinical trials. Two experienced renal pathologists, 
blinded to the clinical data, scored the biopsies. The model could successfully 
predict renal survival with ascending prognosis categories of sclerotic, mixed, 
crescentic, and focal classes, respectively (133).  
 




Normal      Crescentic 
      
Crescentic     Sclerotic 
          
Figure 3. Examples of glomerular lesions: Normal glomerulus (upper left). Glomeruli with extracapillary proliferation and 
crescent formation (upper right and lower left). Global glomerulosclerosis with obliteration of the glomerulus (lower left). 
Glomeruli have been stained with periodic acid-Schiff. Courtesy of Leif Bostad 
 
Until recently, twelve studies have validated the classification model 
(Table 7). The model is of predictive value for renal outcome, especially for 
focal and sclerotic classes. In the crescentic and the mixed classes, there are 
conflicting results in the literature. The discrepancy in outcome might be due 
to differences in ethnicity, ANCA specificity, and variations in treatment 
between the studies (132, 233, 234).  
A high percentage of normal glomeruli in the biopsy specimen is a good 
predictor of favourable renal outcome. Patients with globally sclerotic 
glomeruli at baseline are associated with a poor response to treatment and 
are at an increased risk of developing ESRD. The percentage of crescentic 
glomeruli is associated with good renal recovery and these patients benefit 
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from therapy. These pathologic lesions are of prognostic value independently 
of the baseline eGFR. Tubulointerstitial inflammation and alterations might 
also be of prognostic value, but previous studies have shown inconsistent 
results. Moreover, an inclusion of this variable could further decrease the 
reliability of the classification scheme. Interestingly, compared to patients with 
PR3-ANCA, patients with positive MPO-ANCA have more chronic lesions at 
diagnosis, and poorer renal outcome (131, 234-236).  
 
Table 7. Summary of studies validating the 2010 histologic classification model  




1 year Renal 
Survival (%) 
5 year Renal 
Survival (%) 
ESRD or death  
(n (%)) 
Berden A.(133) 2010 100 16/55/16/13 93/84/69/50 93/76/61/50 ESRD: 1(7)/11(25)/ 
6(46)/7(70) 
Chang DY.(233) 2012 121 33/53/24/11 100/73/83/29 93/60/72/29 ESRD: 3(9)/15(28)/ 
4(17)/8(73) 
Muso E.(237) 2013 87 40/7/26/14 100/86/96/35 100/86/96/29 NR 
Ellis CL. (238) 2013 76 20/18/27/11 90/78/81/73 NR NR 
Hilhorst M.(239) 2013 164 81/43/39/1 NR 91/64/69/- NR 
Unlu M.(240) 2013 141 31/69/29/12 NR NR ESRD: 4(13)/20(29)/ 
10(34)/8(67) 
Iwakiri T. (241) 2013 102 46/32/18/6 NR NR ESRD: 2(4.3)/9(28)/ 
8(44)/4(67) 
Ford S. (242) 2014 120 34/33/33/20 NR NR ESRD or death: 
11(32)/14(42)/13(39)/
16(80) 
Togashi M. (243) 2014 54 17/8/19/10 2/22/11/33 NR ESRD: 2(4)/9(28)/ 
8(44)/4(67) 




Noone D. (244) 2014 40 13/20/2/5 77/55**/0 NR ESRD: 0(0)/9(41)**/ 
5(100) 
Tanna A. (234) 2015 104 23/26/48/7 100/74/85/50 100/74/77/25 NR 
*Class: Focal/Crescentic/Mixed/Sclerotic 




1 Aims of the study 
The overall aim of this thesis was to explore the prognosis and estimate 
potential prognostic risk factors in patients with ANCA-GN. To investigate 
this, our objectives were as follows:  
 
• Paper I: To study the temporal survival and to identify prognostic 
factors in a retrospective cohort of patients with ANCA-GN.  
• Paper II: To investigate the prognostic impact of a histopathologic 
classification in patients with renal biopsy-verified ANCA-GN.  
• Paper III: To explore the occurrence of malignancies in patients with 
ANCA-GN.  
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2 Study Design 
3.1 Participants 
Inclusion criteria 
In all papers, eligible patients had a kidney biopsy with pauci-immune 
glomerulonephritis and a positive ANCA serology. The inclusion of patients or 
cases was limited to the time periods of 1988-2012, 1991-2012, and 1988-
2012 in papers I, II, and III.     
 
Excluded cases 
All patients with missing data or unknown ANCA serology were excluded. In 
paper II, cases with ≤ 2 glomeruli in the biopsy were excluded. In paper III, 
cases with known cancer prior to renal biopsy were excluded.  
 
Observation period 
In papers I and II, patients were observed to progression of ESRD, death, or 
end of follow-up. In paper III, patients were followed to the occurrence of 
cancer, death, or end of follow-up.  
3.2. Data collection and quality registries 
National quality registries contribute to monitoring and improving health 
care services. Systematic collection of treatment and outcome data help to 
assess the quality of medical care and identify areas that need to be 
improved (245). The Norwegian Directorate of Health, based on the need for 
health care improvement in this patient group and data coverage, is 
responsible for deciding whether a registry can be approved as a national 
quality registry. Annual registry reports are evaluated to monitor the quality of 
the data and coverage.  
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In all papers, cases were retrieved from the Norwegian Kidney Biopsy 
Registry (NKBR), which was established in 1988 by Norsk Nyremedisinsk 
Forening, at Haukeland University Hospital, Bergen. The registry has  
national coverage and consists of over 13,000 biopsies (non-neoplastic). The 
biopsy coverage is estimated to be 90%. In addition to morphologic data, 
reported by a pathology department, it also contains clinical, biochemical, and 
immunologic information at the time of biopsy, reported by the local 
nephrologist/physician. All biopsy specimens were also examined by an 
experienced nephropathologist at Haukeland University Hospital. Patients 
have to fill out a consent form before data can be registered in the NKBR. 
The registry was certified as a quality registry in 2012. Information about 
individual therapy is not registered in the NKBR.  
 
Information on renal replacement therapy (RRT) and transplantation were 
collected from the Norwegian Renal Registry. Located at Oslo University 
Hospital, Rikshospitalet, all patients receiving RRT are registered from 1980 
to the present date, and are reported from renal units in Norway. Data is 
reported on patients receiving RRT for chronic renal failure, while treatment of 
acute renal failure is not reported unless it turns out to be an irreversible 
failure. It is estimated to be a complete reporting based on annual 
crosschecks.  
 
Deaths were retrieved from the Norwegian Population Registry where 
all deceased are compulsorily registered from death-certificates according to 
their unique 11-digit identification number. Causes of deaths were retrieved 
from the Cause of Death Registry, Statistics Norway. The registry was 
established in 1951, and information of the causes of deaths is obtained by 
standardised form, filled out by a physician. In 2014, the completeness of the 
registry was approximately 98% (http://statistikkbank.fhi.no/dar/). In our study, 
we categorised cause of deaths into active vasculitis, infection, 
cardiovascular disease, malignancy, or other causes.  
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In paper III, malignancies were identified from the Norwegian Cancer 
Registry (NCR). With the exception of basal cell carcinoma of the skin, the 
registry has a near complete registration, estimated to be 99% (246). Since 
1953, the registration of malignancies has been mandatory, and information 
is gathered from clinical and pathological reports and death certificates. The 
registry contains data of annual gender-specific incidence rates of cancer 
categorised by organ system, reported at 5-year intervals, stratified by age 
and time period.  
 
In paper I, a standardised email survey was sent out to hospitals to 
collect information regarding maintenance treatment preferences and the 
availability of ANCA serology. 
 
3.3 Definition of end-points and predicting factors 
In all of the papers, ESRD was defined as commencement of renal 
replacement therapy with chronic dialysis or transplantation. Nephrotic-range 
proteinuria and low serum albumin were classified as ≥ 3 grams per 24 hours 
and ≤ 30 grams per litre, respectively. Hypertension was defined as ≥ 140/90 
mmHg.  
ANCA subgroups were categorised as C-ANCA/PR3-ANCA or P-
ANCA/MPO-ANCA.  
 
In paper I, the cohort was divided into an early and a late group 
diagnosed before or after December 31st, 2002. Furthermore, patients were 
also categorised into age groups (< 60 years, 60-74.9 years and ≥ 75 years) 
and mean eGFR either < or ≥ 15 ml/min per 1.73 m2.   
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In paper II, all biopsies were evaluated and classified according to the 
histopathologic classification model (133); ≥ 50% of visible glomeruli with 
global sclerosis was sclerotic class, ≥ 50% normal glomeruli was focal, ≥ 50% 
crescentic formation was crescentic class, and all other were classified as 
mixed. In addition, we merged crescentic and mixed classes in the sub-
analysis. Separate analyses were performed for cases with 3-9 and ≥ 10 
glomeruli.  
 
In paper III, the cohort was categorised into NMSC and non-NMSC 
subgroups. In the non-NMSC group, person-year at risk was calculated up to 
the occurrence of other cancer type, end of follow-up, or death. In patients, 
who have undergone transplants, the person-year at risk started from the 
date of kidney transplantation.   
 
3.4. Statistical methods 
General 
Statistical analyses were calculated using the Statistical Package for 
the Social Sciences; SPSS for Mac and Windows, version 22 and 23, and 
STATA.  
Continuous and categorical variables were compared with Mann-
Whitney U-test, Chi square test (X2), or Fisher’s exact test. A two-tailed p-




Comparisons of survival rates between study groups were calculated 
with the Kaplan-Meier method and the log-rank test. In paper I, a 
standardised mortality ratio (SMR) was calculated to compare the study 
cohort with the general population. The SMR was defined as the ratio 
between expected and observed deaths in the study population. The 
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expected number of deaths was the sum of the mortality risk in each person-
year of follow-up in an age and gender matched general population, retrieved 
from Statistics Norway.  
  
Standardised incidence ratio  
In the last paper (III), a SIR was calculated to compare the occurrence 
of malignancy in the study population to a matched general population. The 
expected number of cancers is the sum of the risk in each person-year of 
follow-up of an age- and gender-matched general population. The confidence 
interval was calculated by assuming Poisson distribution of cancer frequency. 
Furthermore, subanalyses for the SIRs were calculated for time after 
diagnosis, gender, ANCA specificity, and kidney transplantation. In addition, a 
pooled-analysis was conducted by estimating expected and observed 
cancers from recent studies describing patients diagnosed with AAV after 
1988 (227-229, 247), including results given in paper III.   
 
Regression models 
A Cox regression model was used in multivariate analysis to calculate 
the hazard ratio (HR) after adjustments for known confounders in all papers.  
In paper II, a logistic regression analysis was utilised to create a clinical 
classification model containing eGFR, age, gender, and ANCA subtype. 
Additionally, a separate model was calculated with combined clinical and 
pathologic parameters.  
 
ROC Curve 
In paper II, a receiver operator characteristic (ROC) curve was 
calculated to test the performance of the histopathologic classification 
scheme in predicting development of ESRD during the first year after 
diagnosis. The curve reflects the ratio of true positive and false positive rates. 
Calculation of the area under the curve (AUC) will range from 0.0 to 1.0, 
where 1.0 reflects a perfect predictor and 0.5 is equivalent to random 
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guessing. AUC was calculated first for the histologic model, and then for a 
clinical model with age, sex, ANCA subtype and eGFR. Lastly, AUC was 
calculated for a merged model including both histologic and clinical 
parameters. 
3.5 Ethics 
The studies were approved by the Regional Committee for Medical and 
Health Research Ethics (REC South-East, 2013/1083).  
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4 Results 
4.1 Paper I – The Prognosis in Patients with ANCA-GN 
The cohort of 455 patients with ANCA-GN was followed for a mean 6.0 
years (range, 0-23.4 years). During follow-up, 124 (27%) progressed to 
ESRD, 69 (15%) within the first year after diagnosis. Cumulative ESRD-free 
survival at 5, 10, and 15 years was 75%, 68%, and 58%, respectively. A total 
of 165 patients died during follow-up, 75 within the first year after diagnosis. 
The most common causes of deaths were cardiovascular disease (n = 58), 
infection (n = 43), and active vasculitis (n = 31).  
Compared to the general population, there was a 2.8 fold increased risk 
of death in the study cohort, and a 10.8 fold higher mortality rate within the 
first year. In multivariate analysis, independent risk factors for ESRD were 
initial eGFR < 15 ml/min per 1.73 m2 (HR 5.1, 95% CI; 3.5-7.4), male gender 
(HR 2.1, 1.4-3.1) P/MPO-ANCA (HR 1.8, 1.2-2.6), proteinuria ≥ 3 gram per 24 
hours (HR 1.7, 1.1-2.4), and blood pressure ≥ 140/90 mmHg (1.9, 1.2-2.9). 
Independent risk factors for death within the first year of follow-up were eGFR 
<15 ml/min per 1.73 m2 (HR 2.2, 95% CI; 1.4-3.5), age group 60-74.9 (HR 
4.0, 1.8-8.1), and ≥ 75 years (HR 8.4, 3.8-18.6).  
When comparing the time periods of 1988-2002 and 2003-2012, 
baseline characteristics show that the latter study group was significantly 
older (57.6 versus 61.5 years, p = 0.02), higher percentage of P-ANCA 
positive patients (76 (35%) versus 121 (51%), p < 0.001), lower rate of 
proteinuria at diagnosis (2.1 versus 1.6 gram per 24 hours, p = 0.01), and 
higher mean eGFR at diagnosis (27 versus 37 ml/min per 1.73 m2, p < 
0.001). Patients diagnosed before 2003 had a significantly higher risk of 
developing ESRD compared to those diagnosed between 2003 and 2012, but 
the result was not significant after adjustment for eGFR. Mortality within the 
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first year and in the age group ≥ 60 years old was significantly higher in 1988-
2002 compared to the later period.  
 
Figure 4. Kaplan-Meier plot showing renal survival in 455 patients with ANCA-GN categorised by the early (1988-2002) and 
late (2003-2012) study periods, p = 0.03. 
Multiple Cox regression analysis comparing the risk of ESRD during total follow-up between the early and late study group in 
patients with ANCA-GN. HR (95% confidence interval), adjusted for age, gender, ANCA, and eGFR 
4.2 Paper II – A Histopathologic classification of ANCA-GN 
In this study, 250 cases with ≥ 10 glomeruli in the renal biopsy 
specimen were included and classified according to the histopathologic model 
into the categories focal (38%), mixed (24%), crescentic (28%), and sclerotic 
(9%). After a median follow-up time of 3.5 years, the primary end-point, 
ESRD, had occurred in 60 patients (24%).  
The cumulative proportions of renal survival at 1 and 5 years were 96% 
and 90%, 86% and 75%, 81% and 69%, 56% and 51% for the focal, mixed, 
crescentic, and sclerotic class, respectively (p < 0.01). In multivariate 
analysis, the sclerotic class had a significantly worse prognosis than the focal 
(HR 9.65; 95% CI, 2.4-39.2) and mixed/crescentic classes (HR 3.3; 95% CI, 
1.4-7.6), respectively. Interestingly, results were only significant within the first 
year after biopsy. No significant difference in mortality was observed between 
the histologic classes.  
Cox Regression Model for ESRD 
 N Events Adjusted HR 
2003-2012 237 44 1.0  
1988-2002 218 80 1.2 (0.8-1.7) 
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In ROC analysis, the AUC was calculated to be 0.72 (95% CI, 0.7-0.8), 
0.79 (95% CI, 0.7-0.9), and 0.79 (95% CI, 0.7-0.9) for the histologic, clinical, 
and the combined classification model, respectively. Equivalent predictive 
results were demonstrated when applying the model in cases with 3-9 
glomeruli. 
 
Figure 5. Kaplan-Meier plot showing the cumulative risk of developing end-stage renal disease in 250 patients with ANCA-GN, 
categorised according to the histopathological classification model (p < 0.001). 
4.3 Paper III – The Risk of Cancer in Patients with ANCA-GN 
Four hundred and nineteen patients were followed for a median length of 
5.7 years (interquartile range, 2.8 to 11.3). Forty-one patients developed 46 
cancers during a total of 3010 person years at risk. Patients who developed 
cancer were older (65 versus 61; P = 0.04), predominantly males (71% 
versus 53%; P = 0.03), and had higher overall mortality (25 (61%) versus 123 
(33%); P < 0.001).  
SIR for all cancers and non-NMSC was 1.09 (95% CI, 0.8 to 1.5) and 0.96 
(95% CI, 0.7 to 1.3), respectively. The occurrence of cancer was highest 1 to 
5 years after renal biopsy, with a SIR of 1.53 (95% CI, 1.0 to 2.3). The risk of 
cancer was significantly increased in NMSC, haematologic malignancies (two 
cases of chronic lymphocytic leukaemia and two cases of myelodysplastic 
syndrome), and among patients, who had undergone renal transplants, with a 
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SIR of 3.40 (95% CI, 1.6 to 7.1), 3.52 (95% CI, 1.3 to 9.4), and 2.12 (95% CI, 
1.0 to 4.4), respectively. No significant risk increase was observed in 
subanalyses of gender and ANCA specificity.   
The risk of cancer was assessed in a pooled-analysis of 1532 patients 
with 236 cancers. During 8801 patient years at risk, SIR was estimated to 
1.72 (95% CI, 1.5 to 2.0) for all cancers and 1.21 (95% CI, 1.0 to 1.5) for non-
NMSC, respectively.  
 
       
 
Figure 6. (Left) Kaplan Meier plot showing the cumulative cancer-free survival for 419 patients with ANCA-GN. 
(Right) Primary cancer occurrence in patients with ANCA-GN. NMSC (7 cases), lung (7), prostate (5), haematologic (4), 
urinary bladder and ureter (3), rectum (3), colon (2), uterus (2), central nervous system (2), unknown primary site (2), thyroid 







5.5 Paper I - The Prognosis in Patients with ANCA-GN  
AAV is currently a chronic disease in which patients survival relies on 
immunosuppressive therapy. Quality longitudinal data is pivotal in monitoring 
long-term morbidity and mortality in this patient group. Although previous 
studies have indicated that patients with AAV live longer with the disease 
today, poorly standardised definitions, lack of hard end-points and a 
representative study cohort, have hampered the interpretation of the study 
results. Whether or not the changes in therapy over the last 5 to 6 decades 
have had a favourable impact on prognosis needs to be elucidated further in 
an unselected population. One of the aims of the NKBR is to evaluate the 
quality of medical care by studying the effect of diagnostics and therapy on 
temporal outcome.      
 In this biopsy-verified retrospective population-based cohort, we 
demonstrated an improved temporal prognosis in both patient and renal 
survival in patients with ANCA-GN. Short-term mortality was 61% higher in 
patients diagnosed between 1988 and 2002 compared to those between 
2003 and 2012. Moreover, in elderly patients, there was a 2-fold increase in 
risk of death. This reflects both the advances in immunosuppressive 
treatment during the last few decades and the introduction of a rapid tool, 
ANCA serology, in the late 1980s. In addition, we postulate that increased 
awareness among clinicians has resulted in earlier detection and initiation of 
therapy, before irreversible organ damage occurs. This is demonstrated by 
our observation, that, after adjustment for baseline renal function, there is no 
significant change in renal prognosis between the different time periods. 
Therefore, baseline renal function might act as a marker of time to disease 
detection. A German single centre study by Holle et al. also demonstrated a 
trend towards earlier diagnosis; the interval between occurrences of 
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symptoms and diagnosis was reduced from 8 to 4 months during the last 4 
decades (208).  
 
Despite the progress in therapy, mortality still remains high. In our 
cohort, during the 1-year and long-term follow-up, the survival rate was 
estimated to be 16% and 37%, respectively. This trend is in agreement with 
reports from other observational studies (3, 182, 183, 188, 191-193, 208, 
248). In our cohort, we observed a 2.8-fold higher mortality rate compared to 
the general population. The risk was substantially higher during the first year 
(SMR 10.8) after diagnosis, especially for older patients with impaired renal 
function. In subsequent years, the mortality ratio increased 1.7-fold compared 
to the general population. Our result correlates well with reports from clinical 
trials, which had an overall and subsequent mortality ratio of 2.6 and 1.3, 
respectively (3). This despite the fact that elderly patients and cases with lung 
haemorrhage were not enrolled in clinical trials. In addition, in a British case-
control study of patients with WG, there was a 9-fold excess mortality during 
the first year after diagnosis compared to matched controls, while it was more 
comparable in subsequent years (198). Hence, it can be assumed that 
current national therapy regimens and follow-up protocols are up to the 
standard of international recommendations.  
The most common causes of death within the first year after diagnosis 
are treatment and disease-related complications, which highlights the need to 
consider the risks and benefits of therapy in this patient group. During long-
term follow-up, the most frequent cause of death in patients without ESRD 
was related to cardiovascular diseases, whereas patients who developed 
ESRD died due to infections. These observations underscore the negative 
impact of both the systemic vascular damage of AAV and the adverse effects 
of cumulative immunosuppression with CYC and corticosteroids.   
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The cumulative risk of ESRD at 1, 5, and 10 years was 16%, 25%, and 
32%, respectively. Importantly, the cumulative 1-year risk of ESRD fell from 
19% to 13% from 1988-2002 to 2003-2012, respectively. A partial explanation 
might be that patients are diagnosed at an earlier stage of disease course, 
with better baseline renal function (27 versus 37 ml/min per 1.73 m2 in 1988-
2002 and 2003-2012, respectively). The trend towards declining ESRD has 
also been described in other European cohorts (182, 208).   
In our cohort, older age and low baseline eGFR were negative 
predictors of both death and ESRD. These patients, in particular, are 
susceptible to treatment-related toxicity and severe infections (3). Similar to 
these findings, Luqmani et al. (198) showed that during 5 years of follow-up, a 
20% mortality rate was observed in 28 patients with renal GPA compared to 
no mortality in 22 patients with nonrenal GPA. Male patients had a higher risk 
of developing ESRD, but no significant sex difference was observed in 
mortality. In contrast, Holle and colleagues reported, in a historic single centre 
cohort of patients with WG, an almost 2-fold higher death ratio for men 
compared to the general population, while the risk was not significantly 
different for females (208). P-ANCA/MPO-ANCA positivity was a negative 
predictor of ESRD, which is associated with more advanced renal damage 
with irreversible scarring (53, 132, 188, 202). Interestingly, ANCA specificity 
had no predictive value on mortality in our cohort. This observation is 
supported by some studies (3, 53), but contradicted by others (249, 250). The 
reported discrepancy in the literature is probably due to the different 
composition of ANCA subtypes between the geographical areas, case 
inclusion from single or specialised centres that might result in selection bias, 
unadjusted mortality rates, or classification bias of ANCA specificity. Lastly, 
the percentage of patients with renal manifestations might vary between 
studies.   
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5.2. Paper II - A Histopathologic Classification of ANCA-GN 
There are few established biomarkers in AAV, and repeated invasive 
biopsies are not desirable. Traditionally, biopsies were associated with 
inconsistent findings and had poor reliability and validity (251, 252). In 2010, 
a landmark study successfully predicted long-term ESRD by developing a 
histopathologic classification model (133). However, this model needs to be 
validated in other cohorts before it can be implemented in routine practice. A 
good prediction model, based on a baseline biopsy specimen, could aid the 
choice of therapy and diminish the need for additional biopsies. The NKBR 
contains one of the world’s largest biobanks of kidney biopsies. Based on this 
registry, in the present validation study, we classified 250 biopsies according 
to the histopathologic classification model, as proposed by Berden and 
colleagues (133).  
Our results show that this model is a moderate predictor of ESRD, 
particularly of the first year after baseline biopsy. Renal survival was best in 
the focal phenotype, with well-preserved renal function over time. The 
sclerotic class had the worst renal outcome, with almost 50% of cases 
progressing to ESRD within 5 years of follow-up, reflecting the severe 
irreversible scarring of the glomeruli. Patients in the sclerotic group are less 
likely to receive plasmapheresis, prednisone, and/or CYC (236), and have a 
poorer response to treatment (253). Nevertheless, our data shows that 50% 
of them regain renal function, and they should therefore receive induction 
therapy with immunosuppression. The mixed class had a slightly better 
prognosis than the crescentic class, with a cumulative 5-year renal survival of 
75% and 69%, respectively. This is in contrast to reports by Berden et al. 
where 5-year survival was estimated to be 61% and 76% for these subgroups 
(133). A Japanese group has also observed a superior outcome in the 
crescentic category compared to the mixed class (241). However, the 
proportion of normal and sclerotic glomeruli was higher in the mixed than the 
crescentic class, which makes the discrepancy difficult to interpret. A likely 
explanation for the conflicting results in the literature between the mixed and 
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the crescentic class might be a difference in the percentage of normal 
glomeruli in the different classes between the studies, different study 
populations or therapy, average inter-rater reliability (242), or the lack of 
inclusion of tubulointerstitial changes (235). Nonetheless, most validation 
studies demonstrate similar eGFR and renal survival in patients with 
crescentic and mixed class biopsies (233, 234, 236-240, 242-244, 253). The 
mixed category might be too heterogeneous as a class to have a prognostic 
value. Thus, we suggest merging the mixed and crescentic classes to better 
utilise the classification model in clinical settings.  
 
So far, four of the validation studies included more than 100 cases in 
the study cohort (133, 233, 234, 239). Merging the cumulative ESRD-free 
survival rate yielded a 1-year risk of 2%, 21%, 23%, and 57% for the 
phenotypes of focal, mixed, crescentic, and sclerotic, respectively. These 
estimates are equivalent to survival data observed in our study, which 
supports the predictive value of the histopathological model of renal outcome 
in patients with ANCA-GN.  
 
In multivariate analysis, independent of baseline renal function, the 
sclerotic phenotype had a 9- and 3-fold higher risk of developing ESRD than 
the focal and mixed/crescentic classes, respectively. No difference in survival 
was observed between focal and mixed/crescentic classes, which highlights 
the negative impact of a low baseline eGFR. At the time of biopsy, renal 
function was significantly higher in patients with the focal phenotype 
compared to mixed and crescentic (54, 27, and 18 ml/min per 1.73 m2; p < 
0.001). A previous Norwegian report of patients with WG by Aasarød and 
colleagues has also described that baseline serum creatinine correlates well 
with the percentage of glomeruli with crescents and necrosis in the biopsy 
specimen (131). Other studies also showed a correlation between baseline 
renal function and the percentage of normal glomeruli (133, 233, 238).  
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The classification model assessment with ROC statistics showed that 
the histologic classes were of moderate quality for predicting renal outcome, 
with an estimated AUC of 0.72. In comparison, clinical parameters (age, 
gender, ANCA serology, and eGFR) yielded a higher AUC of 0.79, which 
strengthens the known prognostic value of age and baseline eGFR in long-
term renal survival. Combining the two variables did not improve the model fit, 
with an AUC of 0.79. One should, however, interpret these results with 
caution, as the study sample is relatively small and other parameters, such as 
tubulointerstitial changes. The number of normal glomeruli and treatment 
were not incorporated in the models.  
 
In their original paper, Berden et al. (133) stated that at least 10 
glomeruli should be present in the biopsy specimen for adequate 
classification. However, in this paper, we have shown an equivalent 
prognostic value of the model in the excluded group of biopsies with 3-9 
glomeruli. Ford (242) and Unlu (240) have also validated the model in their 
cohort of 120 and 141 biopsies with no minimum requirement for number of 
glomeruli required.  
 
In conclusion, renal survival is best in patients with biopsies with the 
presence of the acute phenotypes of focal, mixed, and crescentic, and worst 
in sclerotic lesions. The ascending category order of focal, mixed, crescentic, 
and sclerotic class corresponded to the risk of ESRD at baseline, at 1- and at 
5-year follow-up. However, assessing the performance of the 
histopathological classification model showed only an average predictive 
accuracy, and did not improve model fit compared to established clinical 
predictors. In the future, pathologists should perhaps report the biopsy 
findings with a breakdown into phenotypes of focal, sclerotic, or 
mixed/crescentic category with the percentage of normal glomeruli.    
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5.3. Paper III - The Risk of Cancer in Patients with ANCA-GN 
Treatment-related malignancy due to heavy exposure to 
cyclophosphamide has previously been described in several studies. There is 
a well-known dose- and duration-dependent cancer risk associated with CYC, 
which is the first line therapy for AAV. In paper I, we showed that malignancy 
was a common cause of death in patients with ANCA-GN. We illustrated this 
further in paper III, where we investigated the occurrence of cancer in a 
nationwide cohort of patients with ANCA-GN. We demonstrated that during 
3010 person years at risk, the occurrence of malignancy was 9% higher in 
this patient group compared to a matched general population, although a 
non-significant result (139, 155, 226).  
Our finding is discrepant to previous studies on this topic (97, 101, 226-
229, 232, 247); however, it is comparable with a German study of 445 
patients with WG that showed an overall SIR of 0.8 (208). The discrepancy 
between our result and other studies probably reflects the fact that previous 
reports consisted of an older study population, which does not represent 
contemporary heterogeneous population receiving therapy. The landmark 
clinical trials on CYC-sparing regimens were published during the last 15 
years (118-120, 158). In addition, several studies are limited by a relatively 
small study sample with short observation periods (101, 226, 227, 254). 
Another reason for the inconsistency might be that basal cell carcinoma of the 
skin is not registered in the NCR, and with squamous cell carcinomas, only 
one case per patient is included in the SIR calculations. Consequently, this 
methodological practice has probably underestimated the overall quantitative 
role of skin cancer in our study. However, most recent studies were from 
either tertiary centres (227, 229, 247) or included patients enrolled in clinical 
trials (228), limiting the generalizability of the results. Conversely, our study 
consists of an unselected nationwide population of patients with ANCA-GN, 
which limits the potential selection bias of the study cohort.  
Pooling the SIR data from recent cohort studies on malignancy in AAV 
showed that the risk was 1.72-fold increased for all cancers. This finding is 
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comparable with the 1.74-fold risk increase shown in a recent meta-analysis 
of patients with AAV. However, this meta-analysis included a heterogeneous 
group of studies with a wide follow-up period ranging from 1966 to 2008 
(255).     
  
The borderline increase in overall SIR in our study was attributed to a 
high incidence of NMSC, which is associated with a significantly increased 
malignancy rate, compared to the general population. After exclusion of all 
cases with NMSC, the SIR decreased from 1.09 to 0.96. This finding confirms 
the results from studies by Heijl (228), Rahmattulla (229), and van Daalen 
(247), who showed that the overall risk of cancer was solely attributed to 
NMSC. However, in our pooled analysis of patients with non-NMSC, there 
was a 1.21-fold significant risk increase compared to the general population. 
NMSC occurs frequently in patients receiving immunosuppressive therapy 
and is responsible for over 90% of all skin cancers in patients, who have 
undergone transplants (230).  NMSC is particularly associated with exposure 
to the immunosuppressive drug, azathioprine (101, 228, 229, 231, 256). The 
increased rate of NMSC was also observed in our study and vigilant 
dermatologic screening is advised in this patient group as part of routine 
follow-up. Novel biologic treatment with rituximab might have a protective 
effect in the development of NMSC, but this observation needs to be 
elucidated further (247). 
 
Although there were many cases of haematologic malignancies in our 
cohort, none were acute myeloid leukaemia, which is strongly associated with 
CYC (226-228). Thirty percent of patients with myelodysplastic syndromes 
do, however, develop acute myeloid leukaemia (257). However, to our 
knowledge, no study has shown an association between AAV and chronic 
lymphocytic leukaemia. Although, there was a high occurrence of 
haematologic cancers in our cohort, which are known to occur with long 
latency (258), the majority of malignancies in our cohort occurred 1-5 years 
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after diagnosis. Interestingly, there was no increased risk of lymphomas or 
bladder cancer in our cohort. These malignancies are traditionally associated 
with patients with ANCA-GN and CYC (101, 138, 221, 222, 232). In contrast, 
previous studies showed a 2.4- to 33- fold increased risk of developing 
bladder cancer and a 1.1- to 11- fold higher risk of developing lymphomas 
(97, 101, 226, 228, 232). Nevertheless, recent groups have shown that the 
cancer risk was only observed in NMSC (229, 247). Our findings confirm the 
findings from these studies that contemporary treatment regimens are 
relatively safe in regards to urothelial cancers.  
 
In subgroup analysis, we showed that there was no increased risk for 
cancer in patients with positive C-ANCA/PR3-ANCA compared to the general 
population. This is in contrast to the increased malignancy risk in patients with 
GPA/PR3-ANCA, described by Rahmattulla et al. (229). The C-ANCA/PR3-
ANCA positive subgroup of patients is susceptible to frequent relapses and 
requires higher cumulative doses of CYC compared to patients with positive 
P-ANCA (161, 229). Furthermore, some studies suggest that they also have a 
more favourable overall survival rate compared to the latter ANCA subgroup 
(249, 250), which might increase the temporal risk of developing cancer. 
However, survival statistics demonstrated that there was no difference in 
mortality between the ANCA groups in our cohort (p = 0.57). Another 
explanation for our finding could be that the rate of relapses and exposure to 
CYC could have been more comparable between the two groups.  
 
In conclusion, the result of this study shows that current treatment 
regimens with CYC in patients with ANCA-GN are not associated with an 
increased overall malignancy risk. We observed, however, an increased 
number of cases of NMSC and haematologic malignancies, which 
emphasises the judicious practice of immunosuppressive therapy in this 
patient group. Larger study samples with longer follow-up are warranted to 
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further investigate the long-term risk of cancer. Meanwhile, frequent follow-
ups and preventive measures against heavy sun exposure are advised. 
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5.4. Methodological considerations and limitations  
The patient sample  
Selection bias 
A selection bias emerges from the lack of comparability between the 
groups being studied. The renal biopsies in the registry are referred from all 
regions of Norway, and therefore are representative of ANCA-GN in Norway. 
However, this limits the external validity of the study since both disease 
phenotype and outcome are known to vary across other regions of the world. 
Furthermore, only patients with renal disease were included in our studies, 
with scarce information of other organ manifestations, which in turn reduces 
the possibility of generalising the results to patients, who do not have renal 
disease. Cases with renal failure where a biopsy was contraindicated are not 
reported. This might lead to an underrepresentation of patient subgroups, 
possibly, with poorer outcome. Furthermore, patients had to fill out a consent 
form before the data could be sent to the NKBR. Information on patients who 
did not fill out the consent form is unknown due to Norwegian privacy 
legislation. However, all biopsies have been examined and reported to the 
NKBR by the pathology departments (p-skjema) independent of clinical 
parameters (k-skjema). Hence, biopsies with missing consent forms could be 
identified and obtained when possible.  
Nevertheless, this is a national population-based quality registry that 
reduces the risk for selection bias to a minimum. In comparison, most studies 
on ANCA-GN are clinical trial-based or from specialised referral centres. 
Majority of patients with AAV develop renal manifestations (90%) and a 
biopsy is considered as the gold standard in the diagnosis of AAV. Thus, it is 
probable that a renal biopsy-based cohort includes the majority of patients 
with AAV (259). 
 
Sample size 
Due to the rare nature of the disease, the sample size is relatively 
small, which might hinder adequate validity of the results. This particularly 
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affects long-term follow up where it becomes increasingly difficult to detect a 
statistically significant difference due to fewer cases reaching an end point. 
Nevertheless, the overall result in all three papers is consistent with previous 




The NKBR has national coverage and gets reports from all hospitals 
with a nephrology unit (25 hospitals). This reduces any chance of referral bias 
to a minimum. 
  
Case definition, case capture, and case ascertainment 
An epidemiologic study of a rare disease, such as ANCA-GN, can pose 
certain challenges that need to be addressed. First, the classification of 
vasculitis has been evolving over the last few decades, and distinction 
between similar diseases based on phenotypical characteristics might not 
always be straightforward. Second, a large population is necessary to include 
a representative amount of cases within a reasonable time frame. Finally, 
hospital-based case ascertainment is appropriate since most patients with 
this condition are being treated in secondary care institutions. In our study, 
we differentiated our cases from other diseases with serologic and histologic 
markers, which are distinct for ANCA-GN. However, this excludes patients, 
who are ANCA negative (10% of AAV) and patients without a biopsy. 
Nevertheless, the inclusion of patients from a population-based registry 
ensures adequate and representative case capture. The registry is based on 
information from secondary care units where most of these patients are 
treated in Norway.  
 
Data collection  
Information bias 
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All papers had a retrospective design; nevertheless, baseline data were 
registered at the time of the biopsy in NKBR with a standardised form (“k-
skjema” and “p-skjema”). However, misclassification or measurement errors 
cannot be ruled out when obtaining clinical, biochemical, or immunologic data. 
Follow-up data, such as regarding ESRD, malignancy, and death were 
acquired from national quality registries and patients with missing or unknown 
data were excluded from the study cohort.  
 
Confounder 
A confounder is a third variable that is associated with the exposure and 
is blurring the effect of exposure on the outcome that is being studied (260), In 
study I and III, the cohort was compared to an age- and gender-matched 
general population, which controls for any confounding effect of these 
demographic variables. Furthermore, multivariate analyses were calculated in 
all three studies where adjustments were made for variables other than the 
studied predictor. Nevertheless, information about comorbidities, such as other 
renal diseases, for example, renal complications of diabetes mellitus, lupus 
nephritis, anti-glomerular basement membrane disease, or exposure to 
environmental toxins, such as smoking, are not available in the NKBR, and 
therefore are not adjusted for in our calculations. In addition, no adjustments 
for treatment, temporal improvement in healthcare, or time from symptoms to 
biopsy, are directly adjusted for in the regression models. However, in paper I, 
by stratifying the cohort into time period and baseline renal function, we 
showed a longitudinal improvement in survival.  
 
Other epidemiologic fallacies, which we should be aware of, are lead-
time bias and length-biased sampling. Lead-time bias occurs when patient 
survival is prolonged after implementation of a screening program. Moreover, 
patients are diagnosed earlier and live longer with their diagnosis, resulting in 
length-biased sampling. These limitations are unlikely in our study due to the 
rapid course of ANCA-GN, with weeks to months from debut of symptoms to 
 79 
renal failure. Any potential lead-time cannot explain several years of improved 
long-term survival. Introduction of ANCA serology could have detected patients 
with localised or indolent disease, thereby showing a spurious improvement in 
overall outcome. Nevertheless, several studies, including ours, have also 




To determine the availability of ANCA serology and practice of therapy, 
an email survey was sent out to all renal units reporting to the NKBR in 
Norway. Despite being standardised with a high response rate, recall bias is an 
inherent weakness of questionnaires. Nevertheless, information gathered with 
the survey was not used in any analyses, but had a more descriptive purpose 
since these data were not obtained in the NKBR.  
 
Paper II 
Although our study found that the histopathologic model was an 
independent predictor in multivariate analysis, it was only of average quality in 
predicting ESRD. However, we cannot exclude the prognostic importance of 
other histologic features, such as tubular atrophy or interstitial fibrosis, since 
these parameters were not included in the standard model. Also, the treatment 
the patients were exposed to prior to biopsy, at baseline and under follow-up, 
is missing in the registry and could not be corrected for in our analyses. 
Nonetheless, our study does provide information on prognosis by histologic 
class in the context of current therapy of ANCA-GN. To investigate this further, 
a large international validation study is currently being performed.  
 
There might also be a problem with lack of inter- and intra-rater 
reliability, since only one pathologist reviewed and classified the biopsies. 
However, all histopathologic data in the NKBR has been examined and 
reported by a local pathologist (“p-skjema”), and re-examined by the 
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nephropathologist at the NKBR at Haukeland University Hospital. Also, in a 
previous study on renal histopathology in systemic vasculitis, good inter- and 
intra-observer agreement was found among four experienced 
nephropathologists when reviewing quantitative data (percentage of normal, 
crescentic, and sclerotic glomeruli) (261). A recent validation study by Ford et 
al. (242) showed good levels of agreement for classifying the sclerotic class 
among three pathologists, but only moderate agreement for classifying the 
remaining classes in the histopathologic classification model. Nonetheless, a 
non-differential misclassification tends to obscure the observed difference 
between the groups studied. Despite this, our finding shows that there is a 
significant difference in prognosis based on the histopathologic classes, after 
adjusting for potential confounders.  
 
Paper III 
The NCR obtains both clinical and pathological data from all health 
regions in Norway. However, the fact that basal cell carcinoma of the skin is 
not compulsorily reported in the NCR is a limitation. This underrepresentation 





SMR was calculated in mortality analyses to compare our cohort with a 
matched general population. The expected number of deaths were retrieved 
and calculated from Statistics Norway. Meanwhile, the observed number of 
deaths was obtained from the Norwegian Population Registry. Despite that the 
retrieval of these two estimates comes from different sources, which might give 
a spurious mortality ratio, the death certificate filled out by the physician is the 
basis for the data in both registries. A potential reporting bias will affect the 
estimates evenly and not alter the mortality ratio.  
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A limitation of SMR statistics is that they have to be interpreted with 
caution when the sample size is small and there are very few deaths to 
compare between the groups studied. Another limitation is that the SMR 
cannot be used to compare different geographical areas, since the population 
mortality profile might vary between areas. Nevertheless, the SMR calculated 
in our study was based on national registries and reflects the Norwegian 
population. Also, a high prevalence of the disease itself in the general 
population could result in an underestimation of the true relative risk with a 
spurious low SMR (262).  
 
Paper II 
The ROC curve statistics are useful for measuring the accuracy of a 
diagnostic test. The AUC is the combined measure of how well the test 
predicts true end-points, in this case ESRD. An advantage with this method is 
that ROC plots are independent of prevalence of the disease. However, their 
value in clinical decision-making can be argued (263). Other studies have used 
continuous outcomes instead of dichotomous outcomes, and thereby also use 
alternative performance measures (multivariate linear regression models).  
 
Paper III 
Both the expected and the observed number of cancers in the SIR 
estimate are collected and reported in the same manner in the NCR. This 
ensures that there is no biased cumulative estimate of malignancies in either 
group, which could give a false SIR estimate. In accordance with the statistical 
practice of the NCR, only the primary occurring cancers were included in SIR 
analysis. This might lead to underrepresentation when comparing the results to 
other countries. However, the Netherlands Cancer Registry also applies this 





To limit potential selection bias of the study cohort with ≥ 10 glomeruli 
(250 patients), we compared it with the group with 3-9 glomeruli (108 
patients), and excluded cases with < 3 glomeruli (87 patients). A Cox 
regression model was utilised to compare the hazard ratios of ESRD between 
the groups when adjusting for age, gender, ANCA subtype, and baseline 
eGFR. In comparison of the group with ≥ 10 glomeruli versus the group with 
3-9 glomeruli, we also adjusted for histologic classification. There was no 
significant difference between the groups in this multivariate analysis on 
ESRD. We can therefore conclude that the risk of selection bias between the 
studied and the excluded group is benign.  
 
Paper III 
Thirty-four patients had known cancer prior to renal biopsy and were 
therefore excluded from the study cohort. There might be an association with 
malignancy prior to AAV development, however, reports have yielded 
inconsistent results (225). Rahmattulla and colleagues have also showed that 
the risk of malignancy is comparable when comparing patients with and 
without a history of cancer prior to the AAV diagnosis (229). A recent group 





Paper I - The prognosis in patients with ANCA-GN 
o Both patient and renal survival has improved significantly in patients 
with ANCA-GN from 1988 through 2012.  
o Improved immunosuppressive therapy, shorter diagnostic delay due to 
ANCA serology, and more awareness among clinicians are important 
causal mechanisms of this trend.  
o Mortality is still 3-fold higher compared to the general population with 
current treatment practices, particularly during the first year after 
diagnosis.  
o Most common causes of deaths are related to disease and adverse 
effects of therapy.  
o Independent negative predictors for short-term mortality were baseline 
eGFR < 15 ml/min per 1.73 m2, older age (> 60 years), and serum 
albumin < 30 g/L.  
o Independent risk factors for long-term ESRD were male sex and 
positive P-ANCA serology.  
 
Paper II - Estimating the predictive value of a histopathologic 
classification model in patients with ANCA-GN 
o The histopathologic classification model purposed by Berden et al. 
(133) significantly predicts renal survival. 
o The sclerotic class had a significantly worse renal outcome compared 
to the focal and mixed/crescentic classes.  
o There was no significant difference between the mixed and crescentic 
class on outcome. We therefore suggest that merging these two 
classes might simplify the future classification scheme. 
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o ROC statistics demonstrated that this histopathologic classification 
model is of moderate quality in predicting ESRD and not superior to 
clinical parameters.  
o We have also validated the classification model in cases with 3-9 
glomeruli in the biopsy specimen.  
Paper III – Incidence of malignancy in ANCA-GN patients 
o The risk of developing malignancy was not significantly increased in a 
Norwegian cohort of patients with ANCA-GN compared to the general 
population. This finding reflects current immunosuppressive therapy, 
with more restrictive use of CYC compared to previous times. 
o There was a higher occurrence of NMSC and haematologic cancers in 
site-specific malignancies. The risk of bladder cancer was not 
increased.  
o NMSC was the most prevalent cancer form and a major contributor to 
the observed cancer prevalence. 
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7 Future perspectives  
o    There is an increased risk of death in patients with ANCA-GN compared 
to the general population and particularly associated with toxic 
immunosuppressive drugs. Future prospective studies are pivotal to 
optimise treatment protocols, more specifically in older patients with 
severe organ damage. Tailoring treatment and prudent clinical monitoring 
are necessary to further reduce the disease burden in this patient group.  
o    We have validated the histopathologic classification model suggested 
by a consortium of international pathologists. However, our study was not 
able to detect any significant distinction between the mixed and the 
crescentic classes. Moreover, neither tubulointerstitial parameters nor 
percentage of normal glomeruli were included in our calculations as 
possible predictors of ESRD. Lastly, due to lack of treatment data in the 
NKBR, no adjustment was made with this regard. To address this further, 
a large and international prospective validation study is warranted.  
o    We did not observe a significantly increased risk of cancer in our cohort 
of patients with ANCA-GN. Nevertheless, there was still a 3-fold higher 
occurrence of NMSC and haematologic malignancies compared to the 
general population. Moreover, some cancer forms can develop after a 
long latent period. Larger studies with longer follow-up are therefore 
necessary to gather sufficient capabilities to detect late-occurring cancer 
cases. In addition, the effect of novel treatment protocols on the 
malignancy risk needs to be investigated in detail. Meanwhile, continued 
efforts in the search for safer and alternative therapies for ANCA-GN are 
warranted.   
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ABSTRACT
Background. Glomerulonephritis associated with anti-
neutrophil cytoplasmic antibodies (ANCA) is associated with
increased mortality and a high risk of end-stage renal disease
(ESRD). Here, we investigated whether the prognosis has
improved over the last 25 years.
Methods. Patients were identified in the Norwegian Kidney
Biopsy Registry. We included all patients with pauci-immune
crescentic glomerulonephritis and a positive ANCA test from
1988 to 2012. Deaths and ESRD in the cohort were identified
through record linkage with the Norwegian Population Regis-
try (deaths) and the Norwegian Renal Registry (ESRD). Out-
comes of patients diagnosed in 1988–2002 were compared
with outcomes of patients diagnosed in 2003–12.
Results. A cohort of 455 patients with ANCA-associated
glomerulonephritis was identified. The mean follow-up was
6.0 years (range, 0.0–23.4). During the study period, 165
(36%) patients died and 124 (27%) progressed to ESRD. Com-
pared with patients diagnosed in 1988–2002, those diagnosed
in 2003–12 had higher mean initial estimated glomerular fil-
tration rates (37 versus 27 mL/min/1.73 m2) and lower risk of
ESRD (1-year risk: 13 versus 19%; 10-year risk: 26 versus
37%). The composite endpoint, ESRD or death within 0–1
year after diagnosis, was reduced from 34 to 25%. In patients
over 60 years old, 1-year mortality fell from 33 to 20%.
Conclusions. In Norwegian patients with ANCA-associated
glomerulonephritis, prognosis was significantly better in
2003–12 compared with 1988–2002. This improvement was
probably partly due to a shorter diagnostic delay, and better
therapeutic management in older patients.
Keywords: ANCA-associated glomerulonephritis, diagnostic
delay, end-stage renal disease, mortality, prognosis
INTRODUCTION
Anti-neutrophil cytoplasmic antibody (ANCA)-associated glom-
erulonephritis (AAGN) is the most frequent form of the rapidly
progressive glomerulonephritis syndrome. AAGN is an import-
ant cause of end-stage renal disease (ESRD) [1, 2]. Prior to the
introduction of modern therapy, the prognosis of AAGN was
very poor, and most patients died within 1–2 years after disease
onset [3]. Cyclophosphamide (CYC) combined with corticoster-
oids (CS) was introduced as a treatment for AAGN more than
4 decades ago. This advent significantly improved prognosis,
but morbidity and mortality remained high for several reasons
[4–9]. First, treatment was often initiated after severe irreversible
organ damage had occurred. Second, some patients had CYC-
intolerance or resistance and, until recently, there were no effective© The Author 2015. Published by Oxford University Press on behalf of ERA-
EDTA. This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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alternative drugs for treatment. Third, both CYC and CS are as-
sociated with severe toxicity, which can be fatal. Fourth, AAGN
often recurred after long periods of remission and, unless recur-
rent episodes were treated promptly, they could cause severe
organ dysfunction, including ESRD [10–12]. Currently, rituxi-
mab has been proven as effective, but not superior, to CYC for
inducing remission in patients with ANCA-associated vasculitis
[13–15]. However, in Norway, CYC remains the first-line treat-
ment for inducing remission in most patients with AAGN.
Despite the lack of new, safe pharmacological substances
that are more effective than CYC, a number of measures have
been taken that could improve the prognosis of patients with
AAGN. The diagnostic delay has probably been reduced by an
increased clinical awareness about AAGN and the availability
of an ANCA analysis that provides an answer within 1–2 days.
The more recent introduction of rituximab has increased the
therapeutic possibilities, particularly for patients with AAGN
that are resistant or intolerant to CYC treatment. Also, opti-
mization of CYC usage in maintenance treatments for AAGN
may have reduced treatment-related morbidity and mortality.
For example, CYC usage may be optimized by reducing doses
for older patients and patients with advanced renal failure; by
transitioning patients from oral to intravenous CYC; and by
substituting CYC with other, presumably safer agents, like
azathioprine (AZA) after achieved remission. Finally, the diag-
nostic delay, and thus, the risk of ESRD may have been
reduced by the increased awareness that life-long surveillance
is necessary to detect recurrence in patients with AAGN [16–19].
A few recent reports have shown an improved prognosis in
patients with ANCA-associated vasculitis over time, but specific
data are limited for patients with biopsy-proven AAGN [20–22].
In Norway, since 1988, all patients with kidney biopsies that
showed AAGN have been registered in the Norwegian Kidney
Biopsy Registry (NKBR). Here, we studied the prognosis in pa-
tients with AAGN and compared outcomes between patients di-
agnosed in 1988–2002 versus those diagnosed in 2003–12. We
hypothesized that Norwegian patients with AAGN have experi-
enced improved survival and reduced risk of ESRD over time.
MATERIALS AND METHODS
This study was approved by the Regional Committees for
Medical and Health Research Ethics (REC south-east).
Registries used in the study
The NKBR was established in 1988. Clinical and histo-
pathological data from patients that underwent a diagnostic
kidney biopsy in Norway (current population, 5 million) were
registered starting in 1988, and the completeness of registra-
tion was estimated to be ∼90%.
The Norwegian Renal Registry is located at Oslo University
Hospital, Rikshospitalet, Norway. Starting in 1980, all patients
that started maintenance dialysis or received a kidney trans-
plant were registered in the Norwegian Renal Registry. The tax
office currently administers the Norwegian Population Regis-
try, and all deaths are registered on a weekly basis. Information
regarding the causes of death is recorded on the compulsory
Norwegian death certificate, and this information is registered
in the Cause of Death Registry, administered by Statistics
Norway. The unique, 11-digit, Norwegian social security number
made linking the different registries simple and reliable.
Identification of the study population
All patients were included when they had a first time
kidney biopsy that showed a crescentic pauci-immune pattern
and a documented positive ANCA test.
Observation period, identification and definition
of study endpoints
The total follow-up (TFU) period of this study started on
the date of the diagnostic kidney biopsy and ended on the date
of death or on 31 December 2012. The observation period was
further stratified into short (SFU = 0–1 years) and long
(LFU > 1 years) follow-up periods. In the TFU period, the
primary endpoints were progression to ESRD [commence-
ment of chronic renal replacement therapy (RRT)] and stan-
dardized mortality ratio (SMR). In the SFU period, the study
endpoints were all-cause deaths, SMR and ESRD. In the LFU
period, the primary endpoints were SMR and ESRD. ESRD
and deaths in the cohort were identified by linking the records
of the study cohort to the Norwegian Renal Registry (ESRD)
and the Norwegian Population Registry (deaths). Causes of
death were identified by linking the study cohort to the
Norwegian Cause of Death Registry; all deaths were categor-
ized by cause, which included active vasculitis, infection,
cardiovascular disease, malignancies and other causes.
Identification and definition of predicting factors
in the study
Predicting factors were identified in the NKBR, and com-
parison groups were defined as follows:
(i) Early versus late study cohorts: patients with diagnostic
biopsies performed before 31 December 2002 (early)
were compared with those with biopsies performed
after 31 December 2002 (late).
(ii) Age groups at time of biopsy: patients were compared in
age groups of <60 years; 60–74.9 years and ≥75 years.
(iii) Renal function groups: pre-biopsy serum creatinine
levels were converted to the estimated glomerular fil-
tration rate (eGFR; modified modification of diet in
renal disease formula, Caucasians). Patients with mean
eGFR ≥15 were compared with patients with eGFR
<15 mL/min/1.73 m2.
(iv) ANCA specificity groups: patients with cytoplasmic
(C)-ANCA (immunofluorescence, IF) or anti-protein-
ase 3 (PR3) (enzyme-linked immunosorbent assay,
ELISA) were compared with those with perinuclear (P)-
ANCA (IF) or anti-myeloperoxidase (MPO) (ELISA).
(v) Proteinuria groups: groups comprised patients with
proteinuria ≥3 and those with <3 g/24 h.
(vi) Blood pressure: groups comprised patients with blood
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(vii) Serum albumin: groups comprised patients with serum
albumin ≥ or <30 g/L.
Mortality analyses
We compared the mortality rate of patients with AAGN to
that of the general population by calculating SMR. The SMR
was defined as the ratio between the observed and expected
number of deaths in the cohort. The expected number of
deaths was calculated based on mortality data for the Norwe-
gian population, stratified by age (20–24, 25–29 years, and so
forth), time-period (1990–94, 1995–99 and so forth) and
gender (Statistics Norway). Each participant had an expected
risk of death that varied depending on age, gender, time-
period and duration of follow-up. Thus, the expected number
of deaths in the study cohort was the sum of all of these risks.
A Poisson distribution for death incidence in the general
population was assumed in calculating the 95% confidence
interval (95% CI).
First, SMR was calculated for the TFU, SFU and LFU
periods. Second, the LFU was stratified into not-RRT and
RRT periods, and the SMR was calculated separately for these
periods. Finally, the above calculations were repeated after the
TFU was stratified into early (1988–2002) and late (2003–12)
study cohorts.
Availability of ANCA test and treatment protocols
for 1988–2012
A questionnaire was sent to hospitals that treated patients
with AAGN to determine the availability and response time of
the ANCA test. The questionnaire also asked whether the insti-
tution practiced substitution of CYC with AZA in maintenance
treatments for AAGN, and when they started this practice.
Statistical methods
Continuous variables are expressed as the mean ± SD and
categorical variables are expressed as the number (%). The
χ2-test was used to compare categorical variables, and the
independent sample t-test was used to compare continuous
variables. A P-value ≤0.05 was considered significant. Kaplan–
Meier statistics were used to compare risks of ESRD and death.
The log-rank test was used to test statistical significance. Cox
regression statistics were used to analyse unadjusted and ad-
justed hazard ratios (HRs) for ESRD and/or death. Two ad-
justed HRs were calculated: the first was adjusted for age,
gender and ANCA specificity; the second was adjusted for the
same factors plus the eGFR.
RESULTS
A cohort of 455 patients with AAGN was identified. The TFU
duration was 2720 patient-years, with a mean follow-up of 6.0
years (range, 0.0–23.4). The mean age was 59.6 years (SD 17),
and 55% of patients were males. Number of patients with pro-
teinuria ≥3 g/24 h was 94 (21%) and with hypertension 262
(58%). Other baseline characteristics are shown in Table 1. The
outcomes of patients in the total study cohort are shown in
Figure 1A. During the TFU period, 124/455 (27%) patients pro-
gressed to ESRD, and of those, 55/124 (44%) later died. Among
the patients who did not progress to ESRD, 110/331 (33%)
died. Thus, during the TFU, 165/455 (36%) deaths occurred.
The cumulative risk of ESRD was 16% at 1 year, 25% at 5 years,
32% at 10 years and 42% at 15 years after the AAGN diagnosis.
In the SFU period (<1 years after diagnosis), 69/455 patients
(15%) progressed to ESRD, and 75/455 (16%) patients died
(Figure 1B). Thirteen patients (3%) died after commencement
of RRT. Thus, at the end of the SFU period, 324/455 (71%)
patients without ESRD were alive, and 56/455 (12%) patients
were alive, but were RRT-dependent.
At start of the LFU period (>1 year), 324 patients were alive
without RRT (Figure 1C). Progression to ESRD occurred in
55/324 (17%) patients. The cumulative risk of ESRD was 13%
at 5 years, 22% at 10 years and 37% at 15 years. During the
LFU period, 90 patients died; of these, 48 patients had not pro-
gressed to ESRD, and 42 patients were established in RRT
before death. At the end of the LFU period, 221 patients were
alive without ESRD and 69 patients were alive with RRT.
Among the 165 deaths during the TFU, the causes of death
were active vasculitis (n = 31; 19%), infection (n = 43; 26%),
cardiovascular disease (n = 58; 35%), malignancies (n = 15;
9%) and other causes (n = 18; 11%). The causes of death in the
different observation periods and in patients with or without
RRT are shown in Figure 1A–C.
In the TFU period, the SMR was 2.8 (95% CI: 2.4–3.3). In
the SFU period, the SMR was 10.8 (95% CI: 8.6–13.5), and in
the LFU period it was 1.7 (95% CI: 1.4–2.1). In the not-RRT
part of the LFU period, the SMR was 1.1 (95% CI: 0.8–1.5),
and in the RRT part, the SMR was 4.3 (95% CI: 3.2–5.8).
Risk factors for ESRD in the TFU period
Several significant, independent risk factors for ESRD were
identified for the TFU period (Table 2), including an initial
Table 1. Baseline characteristics of patients diagnosed with AAGN in the









Mean age, years (SD) 59.6 (17) 57.6 (19) 61.5 (18) 0.02
Age ≥75 years 94 (21) 31 (14) 63 (27) 0.001
Male gender 248 (55) 137 (63) 111 (47) <0.001
C-ANCA 258 (57) 142 (65) 116 (49) <0.001
P-ANCA 197 (43) 76 (35) 121 (51) <0.001
Mean eGFR, mL/
min/1.73 m2 (SD)
32 (29) 27 (26) 37 (31) <0.001
eGFR <15 mL/min/
1.73 m2
153 (34) 95 (44) 58 (25) <0.001
S-albumin, g/L (SD) 31 (7) 31 (6) 32 (7) 0.03
Proteinuria, g/24 h
(SD)
1.8 (1.9) 2.1 (2.2) 1.6 (1.5) 0.01
Systolic BP, mmHg
(SD)
143 (22) 144 (21) 142 (22) 0.33
Diastolic BP, mmHg
(SD)
81 (11) 82 (11) 80 (12) 0.05
ANCA, anti-neutrophil cytoplasmic antibodies; C-ANCA, cytoplasmic/proteinase3
ANCA; P-ANCA, perinuclear/myeloperoxidase ANCA; eGFR, estimated glomerular
filtration rate; S-albumin, serum albumin; BP, blood pressure.
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eGFR <15 mL/min/1.73 m2 (adjusted HR = 5.1), male gender
(adjusted HR = 2.1), P/MPO-ANCA (adjusted HR = 1.8) and
age bracket 60–74.9 years (adjusted HR = 0.7). Furthermore,
other risk factors for ESRD identified for the TFU period were
proteinuria ≥3.0 g/24 h (adjusted HR = 1.7, 95% CI: 1.1–2.4,
P = 0.001) and blood pressure ≥140/90 mmHg (adjusted
HR = 1.9, 95% CI: 1.2–2.9, P = 0.003), but not serum albumin
<30 g/L (adjusted HR = 0.9, 95% CI: 0.6–1.3, P = 0.54).
Risk factors for death in the SFU period
Also shown in Table 2, several significant, independent risk
factors for 1-year mortality were identified for the SFU period.
These included an initial eGFR <15 mL/min/1.73 m2 (adjusted
HR = 2.2), age bracket of 60–74.9 years (adjusted HR = 4.0)
and age ≥75 years (adjusted HR = 8.4). Moreover, an increased
1-year mortality rate was significantly associated with serum
albumin <30 g/L (adjusted HR, 95% CI: 1.1.1–3.1, P = 0.01).
Proteinuria ≥3.0 g/24 h and blood pressure ≥140/90 mmHg
were not significantly associated with increased 1-year mortality.
Comparison of early (1988–2002) and late (2003–12)
study cohorts
Compared with the early study cohort, the late study cohort
had significantly higher initial renal function, measured as the
mean eGFR (37 versus 27 mL/min/1.73 m2), and significantly
fewer patients with eGFRs <15 mL/min/1.73 m2 (25 versus 45%)
(Table 3). As shown in Table 1, there were some important differ-
ences in the baseline characteristics of these cohorts. The late
study cohort had a higher mean age (62 versus 58 years), a larger
fraction of patients ≥75 years (27 versus 14%), a larger fraction of
female patients (53 versus 37%) and a higher frequency of type
P/MPO-ANCA (51 versus 35%) than the early study cohort.
In comparing the two cohorts, we found that, over time,
the 1-year cumulative risk of ESRD decreased from 19 to 13%,
F IGURE 1 : Flow chart shows the outcomes of 455 patients with AAGN in the study cohort. (A) All patients in the TFU period. (B) Patients
included in the short follow-up period. (C) Patients included in the long follow-up period. AAGN, anti-neutrophil cytoplasmic antibody-
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and the 10-year risk decreased from 37 to 26% (Figure 2). In the
Cox regression model, the risk of ESRD changed with different
adjustments. For the early study period, the HR adjusted for
age, gender and ANCA was 1.6. However, after adding an ad-
justment for the initial eGFR, the HR decreased to 1.2, and the
difference between cohorts was not significant (Table 4).
In comparing the two cohorts, we found that the 1-year
mortality rate decreased over time from 18 to 15% and it
decreased from 33 to 20% in those ≥60 years old (Figure 3).
In multivariate analyses, the unadjusted HR for 1-year mortal-
ity (1.3) was not significantly different in the early compared
with the late study period (Table 4). When this was adjusted
for age, gender and ANCA (HR = 1.9), it was significantly
higher than that of the late study period. Then, when it was
adjusted also for the initial eGFR (HR = 1.6), it was only bor-
derline significant compared with the late study period. In a
sub-group analysis of patients ≥60 years old, the HR for 1-year
mortality was 2.4 after adjusting for age, gender and ANCA,
and 2.0 after also adjusting for the initial eGFR (Table 4).
In comparing the early and late study groups, we found that,
over time, the risk of the composite endpoint of ESRD or death
<1 year after the AAGN diagnosis (Figure 4) was reduced from
34 to 25% (all patients), from 21 to 13% (patients aged <60
years), from 38 to 25% (patients aged 60–74.9 years) and from
65 to 38% (patients aged ≥75 years). In the Cox regression ana-
lysis, the HR for ESRD or death <1 year after diagnosis was 1.8
after adjusting for age, gender and ANCA, but it decreased to
1.3 (not significantly different from the late study group) after
also adjusting for the initial eGFR (Table 4).
During the SFU period, the difference in SMR between study
groups was only borderline significant. The SMR was 14.8
(10.9–20.2) in the early cohort and 8.1 (5.8–11.3) in the late
cohort. Otherwise, we found no significant differences in SMR
between the early and late study cohorts (data not shown).
Availability of ANCA test and treatment protocols
in 1988–2012
Most hospitals that treated patients with AAGN responded
to our questionnaire. All reported good availability of the
ANCA analysis, and the response time was one to two
working days at most. Historically, all hospitals used CYC to
treat AAGN, but in the last few years, some have used rituxi-
mab for induction and maintenance treatments. All respon-
dents also practiced the substitution of CYC with AZA for
maintenance treatments; this change in practice was intro-
duced between 2003 and 2008 in most hospitals.
Table 2. Multiple Cox regression analyses for ESRD and 1-year mortality in patients with AAGN
Factor N Events Unadjusted HR Adjusted HRa Adjusted HRb
HR for ESRD, TFU period
eGFR ≥15 302 53 1.0 1.0
eGFR <15 153 71 4.07 (2.8–5.8), P < 0.001 5.06 (3.5–7.4), P < 0.001
Female 207 44 1.0 1.0 1.0
Male 248 80 1.58 (1.1–2.3), P = 0.015 1.79 (1.2–2.6), P = 0.003 2.09 (1.4–3.1), P < 0.001
Age <60 years 189 64 1.0 1.0 1.0
Age 60–74.9 years 172 40 0.89 (0.6–1.3), P = 0.562 0.86 (0.6–1.3), P = 0.464 0.66 (0.4–1.0), P = 0.046
Age ≥75 years 94 20 1.09 (0.7–1.8), P = 0.736 1.05 (0.6–1.8), P = 0.861 0.76 (0.5–1.3), P = 0.316
C-ANCA 258 64 1.0 1.0 1.0
P-ANCA 197 60 1.56 (1.1–2.2), P = 0.015 1.78 (1.2–2.6), P = 0.003 1.78 (1.2–2.6), P = 0.003
HR for death, short follow-up period
eGFR ≥15 302 32 1.0 1.0
eGFR <15 153 43 2.97 (1.9–4.7), P < 0.001 2.19 (1.4–3.5), P = 0.001
Female 207 32 1.0 1.0 1.0
Male 248 43 1.16 (0.7–1.8), P = 0.536 1.33 (0.8–2.3), P = 0.241 1.44 (0.9–2.3), P = 0.134
Age <60 years 189 8 1.0 1.0 1.0
Age 60–74.9 years 172 33 4.85 (2.2–10.5), P < 0.001 5.01 (2.3–10.9), P < 0.001 4.02 (1.8–8.1), P < 0.001
Age ≥75 years 94 34 10.15 (4.7–21.9), P < 0.001 10.51 (4.8–23.1), P < 0.001 8.35 (3.8–18.6), P < 0.001
C-ANCA 258 41 1.0 1.0 1.0
P-ANCA 197 34 1.10 (0.7–1.7), P = 0.678 0.85 (0.5–1.4), P = 0.506 0.90 (0.6–1.4), P = 0.657
N, number of patients; HR, hazard ratio; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; ANCA, anti-neutrophil cytoplasmic antibodies; C-ANCA,
cytoplasmic/proteinase3 ANCA; P-ANCA, perinuclear/myeloperoxidase ANCA.
aAdjusted for age, gender and ANCA; P-values compare to the top factor in each sub-group.
bAdjusted for age, gender, ANCA, and eGFR; P-values compare to the top factor in each sub-group.
Table 3. Baseline eGFR, stratified by age and study period
Age group Mean eGFR (SD) P-value Patients with eGFR <15 (%) P-value
1988–2012 1988–2002 2003–2012 Early versus late 1988–2012 1988–2002 2003–2012 Early versus late
All 32 (29) 27 (26) 37 (31) <0.001 34% 44% 25% <0.001
<60 years 42 (34) 35 (30) 52 (37) 0.001 25% 34% 13% 0.001
60–74.9 years 27 (23) 21 (19) 32 (26) 0.002 36% 48% 25% 0.002
≥75 years 23 (22) 17 (17) 26 (24) 0.037 47% 65% 38% 0.016
eGFR, estimated glomerular filtration rates; SD, standard deviation.
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DISCUSSION
The main finding in this study was that the prognosis of
patients with AAGN in Norway improved significantly from
the early (1988–2002) to late (2003–12) study periods. A similar
trend has been described in several other studies in patients
with ANCA-associated vasculitis. However, to our knowledge,
this was the first, nationwide, unselected, population-based
cohort with AAGN confirmed by kidney biopsies [10, 20–22].
A major complication of AAGN is progression to ESRD
[23, 24]. We found that this risk decreased substantially over
time; for the 1-year follow-up, it decreased from 19 to 13%,
and for the 10-year follow-up, it decreased from 37 to 26%.
F IGURE 2 : Kaplan–Meier plots show renal survival in 455 patients with AAGN stratified by early (1988–2002) and late (2003–12) study
periods. (A) All patients. (B) Patients aged <60 years. (C) Patients aged ≥60 years. AAGN, anti-neutrophil cytoplasmic antibodies associated
glomerulonephritis; ESRD, end-stage renal disease.
Table 4. Multiple Cox regression analyses compare the risk of ESRD, the 1-year mortality and the 1-year risk of ESRD or death for patients with AAGN in
1988–2002 versus 2003–12
N Events Unadjusted HR Adjusted HRa Adjusted HRb
HR ESRD 1988–2002 versus 2003–12
2003–12 237 44 1.0 1.0 1.0
1988–2002 218 80 1.54 (1.0–2.3), P = 0.029 1.57 (1.1–2.3), P = 0.026 1.15 (0.8–1.7), P = 0.515
HR 1-year mortality 1988–2002 versus 2003–12
2003–12 237 35 1.0 1.0 1.0
1988–2002 218 40 1.31 (0.8–2.1), P = 0.243 1.87 (1.2–3.0), P = 0.011 1.61 (1.0–2.6), P = 0.056
HR 1-year mortality patients age ≥60 years 1988–2002 versus 2003–12
2003–12 154 30 1.0 1.0 1.0
1988–2002 112 37 1.99 (1.2–3.2), P = 0.005 2.35 (1.4–3.9), P = 0.001 2.01 (1.2–3.4) P = 0.009
HR 1-year ESRD/death 1988–2002 versus 2003–12
2003–12 237 58 1.0 1.0 1.0
1988–2002 218 73 1.49(1.1–2.1), P = 0.02 1.80(1.3–2.6), P < 0.001 1.34(0.9–1.9), P = 0.12
N, number of patients; HR, hazard ratio; ESRD, end-stage renal disease.
aAdjusted for age, gender and ANCA; P-values are compared with the 2003–12 study group.
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This was an improvement of great clinical significance, because
RRT is associated with reduced quality of life, increased mortal-
ity and high costs [25, 26]. The major mechanism of ESRD risk
reduction over time seemed to be a shorter diagnostic delay.
The mean eGFR at AAGN diagnosis increased significantly
over time, from 27 to 37 mL/min/1.73 m2, and the fraction of
patients with eGFR <15 mL/min/1.73 m2 decreased from 44 to
25%. In the Cox regression model, the unadjusted HR for ESRD
in the early period (1.5) was significantly higher than that in the
late period. Moreover, the HR was basically unchanged after
adjusting for age, gender and ANCA sub-type. However, when
we also adjusted for the initial eGFR, the HR dropped to 1.2.
We interpreted this to indicate that the improvement in eGFR
was a mechanistic factor, rather than a confounder.
A primary objective when treating patients with AAGN is
to avoid fatal disease courses. In our study cohort, the mortal-
ity rate was significantly higher than expected for the Norwe-
gian population (SMR 2.8). However, high mortality rates
were only observed in the SFU period (SMR 10.8) and in pa-
tients dependent on RRT during the LFU period (SMR 4.3).
In patients that survived the first year and did not develop
ESRD, the mortality rate was equivalent to that of the general
population, after adjusting for age and gender (SMR 1.1). The
increased mortality rate observed in patients dependent on
RRT was probably not specific to patients with AAGN. We
previously showed similar data for patients with IgA nephro-
pathy [27]. Nevertheless, it underscored the clinical import-
ance of avoiding progression to ESRD in patients with AAGN.
The main concern regarding survival in patients with
AAGN is the high 1-year mortality rate [10]. We did not
observe significantly different short-term mortality rates in the
early (18%) versus late (15%) study periods. However, among
patients with AAGN aged ≥60 years, the 1-year mortality rate
was significantly reduced from 33% (early cohort) to 20% (late
cohort). Of interest, in this age group, the unadjusted HR for
death at 0–1 year after AAGN diagnosis was 2.0 (P = 0.01), and
this HR remained unchanged after adjusting for age, gender,
ANCA type and eGFR. Thus, a shorter diagnostic delay did not
appear to be a major explanatory factor for the improvement in
short-term survival among older patients. We speculated that
the improvement in short-term survival might be due to greater
care taken in treating the older patients in the later compared
with the earlier study period. For example, they may have re-
ceived more frequent use of prophylactic measures, reduced
doses of CYC and more rigorous surveillance, particularly
during the induction phase of the treatment.
F IGURE 3 : Kaplan–Meier plots show 1-year survival in 455 patients with AAGN stratified by study period (1988–2002 versus 2003–12).
(A) All patients. (B) Patients aged <60 years. (C) Patients aged ≥60 years. AAGN, anti-neutrophil cytoplasmic antibodies associated
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The risk of the composite endpoint, ESRD or death, in the
SFU period decreased from 34% (early cohort) to 25% (late
cohort), which clearly indicated a clinically relevant improve-
ment. In death-censored analyses, a reduced mortality rate
could result in an increased risk of ESRD, because death and
ESRD frequently occur concurrently, and they may compete as
endpoints in the clinical setting of AAGN in older patients.
Theoretically, a less toxic, but also less effective, treatment
regimen could result in both decreasing the mortality rate and
increasing the risk of ESRD. However, it was reassuring that,
in our study cohort, the observed improvement in short-term
survival-rate was not linked to an increased risk of ESRD; the
1-year risk of ESRD decreased from 18% (early cohort) to 15%
(late cohort) among patients aged ≥60 years.
The prognosis of patients with AAGN was better in the
LFU than in the SFU period. The mortality risk was, except in
patients with RRT, similar to the age- and gender-adjusted
general population. The annual risk of ESRD was 2–3% per
year of follow-up. Because the death rate did not increase, we
did not investigate the composite ESRD or death endpoint in
the LFU period. In fact, the prognosis of AAGN in the LFU
period was similar to our previous finding in patients with IgA
nephropathy [27]. There were no significant differences in
prognosis between the early as compared with late cohort in
the LFU period.
The overall prognosis in our study cohort was quite similar
to that of previous study cohorts from other countries. A sub-
stantial improvement in renal function at the time of AAGN
diagnosis was also found in a recent study from the Nether-
lands. In that study, serum creatinine fell from ∼450 µmol/L
(in 1979–2000) to 282 µmol/L (in 2001–09) [21]. Most studies
reported that the long-term risk of ESRD was 20–40%, similar
to our findings [9, 20, 28, 29]. Our finding that the 1-year
overall mortality rate was 17% was consistent with previous
reports from unselected study cohorts [21]. Finally, our SMR
of 2.8 closely resembled the 2.7 SMR found in a study on pa-
tients recruited from four clinical European Vasculitis Study
Group (EUVAS) trials [10].
This study showed that the prognosis of AAGN significant-
ly improved from the 1988–2002 period to the 2003–12
period. However, even in the late study period, the 1-year mor-
tality rate was 15%, the 1-year risk of ESRD or death was 25%
and the 10-year cumulative risk of ESRD was 26%. Thus, there
remains room for improvement. Further reduction in diagnos-
tic delay may reduce the risk of ESRD. Optimization of treat-
ment protocols, particularly for older patients, may reduce the
short-term mortality from AAGN [28, 30]. More research is
needed to find new solutions to these challenges.
The major strengths of this study were the large, nation-
wide, population-based, unselected nature of the study cohort
F IGURE 4 : Kaplan–Meier plots show 1-year risk of ESRD or death in 455 patients with AAGN stratified by study period (1988–2002 versus
2003–12). (A) All patients. (B) Patients aged <60 years. (C) Patients aged 60–74.9 years. (D) Patients aged ≥75 years. AAGN, anti-neutrophil
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and the very long observation period with many clinically
important (ESRD/death), reliably identified endpoints. This
study also had some weaknesses. Because the NKBR had a
purely renal focus, we could not categorize patients according
to non-renal vasculitis activity. For example, we could not use
the Birmingham vasculitis activity score. Furthermore, the
histological data in the NKBR were, unfortunately, not suffi-
ciently specific to apply the recently published histopathologic
classification system for AAGN (focal/crescentic/mixed/sclerotic).
Furthermore, we did not have detailed data on individual
treatments; thus, we could not analyse the effects of different
treatment protocols. Another limitation was that patients with
AAGN without kidney-biopsy were not included in the study
cohort, and such patients are not registered in the NKBR.
In summary, we have demonstrated that the prognosis of
AAGN has improved significantly from 1988–2002 to 2003–12.
Nevertheless, morbidity and mortality remain major concerns.
More research is needed to identify strategies that can reduce
diagnostic delay. Development of safer therapeutic strategies is
also needed, specifically for older patients with AAGN.
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Background: Immunosuppressive therapy for antineutrophil cytoplasmic antibody-associated 
vasculitis has been associated with increased malignancy risk.  
 
Objectives: To quantify the cancer risk associated with contemporary cyclophosphamide-
sparing protocols.  
 
Methods: Patients from the Norwegian Kidney Biopsy Registry between 1988 and 2012 who 
had biopsy-verified pauci-immune glomerulonephritis and positive antineutrophil cytoplasmic 
antibody (ANCA) serology were included. Standardised incidence ratios (SIRs) were 
calculated to compare the study cohort with the general population.  
 
Results: The study cohort included 419 patients. During 3010 person-years, cancer developed 
in 41 patients (9.79%); the expected number of cancer cases was 37.5 (8.95%). The cohort 
had SIRs as follows: 1.09, all cancer types (95% CI, 0.81 to 1.49); 0.96, all types except non-
melanoma skin cancer (95% CI, 0.69 to 1.34); 3.40, non-melanoma skin cancer (95% CI, 1.62 
to 7.14); 3.52, hematologic cancer (95% CI, 1.32 to 9.37); 2.12, post-transplant cancer (95% 
CI, 1.01 to 4.44); and 1.53, during the 1-5-year follow-up after diagnosis (95% CI, 1.01 to 
2.32).  
 
Conclusions: Cancer risk did not increase significantly in this cohort with ANCA-associated 
glomerulonephritis. However, increased risk of non-melanoma skin cancer, post-transplant 









Historically, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis 
(AAV) was a fatal disease. The introduction of cyclophosphamide (CYC) treatment in the 
1960s improved the prognosis and made long-term survival possible for patients with AAV 
[1, 2]. However, evidence soon emerged that the long-term survival of patients with AAV 
was associated with significant morbidity including a substantially increased cancer risk [3-7]. 
Immunosuppressive therapy using CYC was particularly associated with malignancy. 
Although the severe adverse effects have elicited a search for less toxic treatment regimens, 
CYC still remains the first-line drug [8].  
High occurrence of cancer has been demonstrated in patients with AAV treated with 
cumulative CYC doses exceeding 36 g [9-11] or when the treatment duration lasted for more 
than a year [4, 12-14]. In the current clinical practice, cumulative CYC doses and treatment 
duration rarely exceed these limits [15-18], which questions the relevance of previous CYC-
associated increased cancer risk observations in patients with AAV. There is a relative paucity 
of data regarding cancer risk in AAV patients treated with current therapy protocols, and to 
our knowledge, only 4 studies have published such data [5, 11, 13, 19]. In these studies, 
increased incidence of malignancy was observed. After excluding non-melanoma skin cancer 
(NMSC) from the analyses, the incidence of malignancy no longer significantly increased in 
any of these investigations. However, these 4 studies were relatively small, with a limited 
statistical power to detect small- to medium-range associations between cancer and AAV. 
Furthermore, most of these reports are single-center studies, which limits their 
generalizability. 
Interestingly, in the most recent study, the standardised incidence ratio (SIR) of all 
cancer types treated with CYC was 4.61 (95% confidence interval (CI) 1.16 to 39.38) times 
higher than that with rituximab-based therapy. However, after excluding NMSC from their 
 6 
analysis, the risk was only 1.30 (95% CI not reported) times higher with CYC compared with 
rituximab-based therapy [19].  
To further investigate the association of cancer and AAV, we analysed data from the 
Norwegian Kidney Biopsy Registry (NKBR) and the Norwegian Cancer Registry (NCR). 
Additionally, we merged data from the present and the 4 recent studies on this topic and 





Materials and Methods 
The study was approved by the Regional Committees for Medical and Health 
Research Ethics (REC South-East 2013/1083).  
 
Study population and registries 
The NKBR was established in 1988. We estimate that ~90% of all kidney biopsies are 
registered. The registry contains morphological, laboratory, and clinical data collected when 
the biopsy was performed. The NCR was established in 1953. Reporting to this registry is 
mandatory and based on reports from clinical and pathological departments and death 
certificates. A near complete registration (98-99%) of solid tumours, except for basal skin cell 
carcinomas, is documented [20]. Annual sex-specific incidence rates for cancer and cancer 
subtypes are available for age groups and time periods in 5-year intervals. These data allow 
for an accurate calculation of the expected cancer case numbers in the study cohort. The 
Norwegian Cause of Death Registry is part of Statistics Norway and based on the mandatory 
Norwegian death certificate. The Norwegian Renal Registry was established in 1980 and has 
registered all patients with end-stage renal disease (ESRD), defined by the commencement of 
maintenance dialysis or receiving kidney transplantation.  
 
Data collection and definitions  
We included patients registered in the NKBR and diagnosed from 1988 to 2012, with 
a pauci-immune necrotising glomerulonephritis and a positive ANCA serology. Patients with 
cancer prior to the AAV diagnosis were excluded. Baseline clinical data, including sex, age, 
ANCA specificity, and estimated glomerular filtration rate (eGFR) (determined by the 
Modification of Diet in Renal Disease equation) [21] were obtained from the NKBR. The 
primary study end-point, cancer incidence, was identified by linking the study cohort with the 
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NCR, using the unique 11-digit Norwegian personal number. Causes of deaths in the study 
cohort were identified through linkage with the Norwegian Cause of Death Registry and 
classified as vascular, malignant, infectious or active inflammation, and other causes. The 
observation period was from the kidney biopsy date to incident cancer, end of 2013, or death, 
whichever came first. Patients with ESRD and those receiving kidney transplants were 
identified through record linkage with the Norwegian Renal Registry. When we calculated the 
cancer risk in transplanted patients, the observation period started from the kidney 
transplantation date.  
 
SIR calculation 
We calculated the SIR as the ratio between the observed and expected cancer case 
numbers in the cohort. The expected cancer case number was calculated as follows: First, the 
number of person-years was calculated in the cohort, stratified by 5-year age groups and 1-
year time periods. Second, this person-time was multiplied with the corresponding incidence 
rate in the general population to get the expected number of cases in each age group and 1-
year period. The total number of expected cancer cases was then calculated as the sum of 
expected cases across age groups and time periods. The observed cancer case number was 
determined by record linkage of the study cohort and NCR using the 11-digit unique 
Norwegian personal number. A Poisson distribution of cancer incidence was assumed when 
95% CIs were calculated. We calculated the SIR throughout the study period and stratified in 
accordance with disease duration periods (0-1, 1-5, 5-10, and >10 years after kidney biopsy), 
sex, ANCA specificity [cytoplasmic ANCA (C-ANCA) or perinuclear ANCA (P-ANCA)], 




A systematic PubMed search was conducted to identify previous studies reporting the 
cancer risk in patients with AAV diagnosed after 1988. The search was restricted to papers 
published in English language. Studies who do not report SIR data were excluded. The SIRs 
were calculated as the sum of the observed cancer cases divided by that of the expected 
cancer cases in all studies.  
 
Treatment 
Information regarding cumulative CYC doses administered to the patients is not 
available in the NKBR. In a previous Norwegian study including patients with Wegener’s 
granulomatosis diagnosed between 1988 and 1998, the majority of patients received 
intravenous CYC with a median cumulative dose of 17 g. In patients receiving oral CYC, the 
median cumulative dose was 48 g [22]. Most centres since approximately 2003 have 
substituted CYC with azathioprine for maintenance treatment, substantially lowering the 
exposure to CYC [23]. In some patients, rituximab has been used for induction and 
maintenance treatment. Some patients have also received plasma exchange treatments [24].  
 
Statistical analyses  
Continuous variables were expressed as medians with 25th and 75th percentiles and 
categorical variables as numbers (%). Comparisons of continuous and categorical variables in 
the baseline characteristics were calculated using the Mann-Whitney U-test and the X2 or 
Fisher’s exact test, respectively. A two-tailed p-value of ≤0.05 and 95% CI was considered 
statistically significant. All statistical analyses were performed using the SPSS software, V.23 





Baseline characteristics  
Between 1988 and 2012, 454 patients diagnosed with AAV and glomerulonephritis 
were identified. Of these, 35 were excluded as a result of cancer diagnosis prior to the 
observation period. Thus, 419 patients were included in the study cohort. As shown in Table 
1, the median age in the cohort was 62 years [interquartile range (IQR), 48 to 72 years], and 
229 (55%) were men. The median eGFR at the time of kidney biopsy was 23 mL/min/1.73 m2 
(IQR, 11 to 46). A positive C-ANCA was found in 237 (57%) and P-ANCA in 183 (43%) 
patients.  
The median length of follow-up was 5.7 years (IQR, 2.8 to 11.3). The mean length of 
follow-up was 7.2 years (SD, 5.8), and the total number of person-years of observation was 
3010. A total of 148 (35%) patients died during the observation period. Causes of deaths are 
registered for 138 patients, of which 69 (50%) died from infectious disease or active 
inflammation/vasculitis, 36 (26%) cardiovascular disease, 12 (9%) malignancy, and 21 (15%) 
from other causes. Kidney transplantation was performed in 60 (14%) patients.  
 
Observed cancer cases 
During follow-up, 46 cancer cases were reported in 41 (9.5%) patients. The first 
occurring cancer cases were as follows: NMSC (7 cases), lung (7), prostate (5), hematologic  
(4), urinary bladder and ureter (3), rectum (3), colon (2), uterus (2), central nerve system (2), 
unknown primary site (2), thyroid (1), ovary (1), lymphoma (1), and pancreas (1). Five 
patients had 2 distinct cancer diagnoses; the second occurring cancer cases were as follows: 
lung (1), NMSC (1), prostate (1), hematologic (1), and stomach (1). Seven patients who 
received transplants were diagnosed with cancer; the first occurring cancer cases were as 
follows: lung (4), prostate (1), lymphoma (1), and NMSC (1). Two of the 5 patients with 2 
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distinct cancers underwent transplant, with the cases of secondary cancer involving the 
prostate and lungs.  
 
Comparison of patients with and without cancer 
The comparison of the patients with and without cancer during follow-up is shown in 
Table 1. The patients with cancer were significantly older [65 years versus 61 years (p=0.04)] 
at the time of AAV diagnosis, and a significantly higher percentage were men (71% versus 
53% (p=0.03). There were no significant differences in eGFR and ANCA specificity between 
those with cancer and those without cancer during follow-up. A higher percentage of patients 
with cancer died during follow-up [25 (61%) versus 123 (33%) (p<0.001)].  
 
Comparison with the general population 
As shown in Table 2A, the SIR of overall malignancy was 1.09 (95% CI 0.81 to 1.49). 
The SIR of all cancer types, except NMSC, was 0.96 (95% CI 0.69 to 1.34). In the 1-5-year 
period after AAV diagnosis, the cancer risk in the study cohort significantly increased 
compared to that in the general population (SIR, 1.53; 95% CI 1.01 to 2.32). The SIR did not 
increase in the first year or >5 years of follow-up after AAV diagnosis. In gender-, ANCA- 
and time period specificity-stratified analyses, SIR of cancer was not significantly increased 
for males of 1.27 (95% CI 0.88 to 1.83), in the C-ANCA positive group of 1.17 (95% CI 0.78 
to 1.74) and in the 1988-2002 time period of 1.14 (95% CI 0.78 to 1.68). Compared to the 
general population, the transplanted patients in the study cohort had a significantly increased 
malignancy risk (SIR, 2.12; 95% CI 1.01 to 4.44), whereas the non-transplanted patients had 
no increased risk (SIR, 0.99; 95% CI 0.71 to 1.39). 
The SIR calculation for the most common site-specific cancer cases showed significantly 
increased risks of NMSC (SIR, 3.40; 95% CI 1.62 to 7.14) and hematologic malignancies 
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(SIR, 3.52; 95% CI 1.32 to 9.37). The SIR did not significantly increase in any other site-
specific cancer type (Table 2B).  
 
Pooled analysis of the 5 cohort studies 
The separate and merged SIRs of all cancer types in the present and the 4 previously 
reported studies are shown in Table 3 and Figure 1. This analysis included a total of 1532 
patients, 8801 patient-years of observation, and 236 cancer cases. The merged SIR of all 
cancer types was 1.72 (95% CI 1.51 to 1.95) and that of all cancer types, except NMSC, was 





In the present study, there was no statistically significant increase in the cancer 
incidence in the patients with AAV and glomerulonephritis compared to the age- and sex-
matched general population (SIR, 1.09; 95% CI 0.89 to 1.49). Excluding the study by Holle et 
al. which reported an SIR of 0.82 (95% CI 0.45 to 1.38) [25], most previous studies, including 
those investigating patients with AAV diagnosed after 1988, have reported a significantly 
increased cancer risk [3-5, 9, 11, 13, 14, 19]. A couple of methodological discrepancies might 
partially explain the contrasting findings between the present and the majority of previous 
studies. First, basal skin cell carcinomas are not registered in the NCR and were thus excluded 
in our analysis. Second, among patients with diagnoses of several cancers, we only included 
the primary cancer when calculating the SIRs. In contrast, other studies have included 
subsequent cancer cases, particularly NMSC, in their SIR estimates.  
The studies investigating cancer incidences in patients with AAV diagnosed after 1988 
reflect contemporary treatment regimens, in which NMSC accounts for the majority of the 
observed increased malignancy risk [5, 11, 13, 19]. In the present study, the SIR decreased 
from 1.09 to 0.96 (95% CI 0.69 to 1.34) when NMSC cases were excluded.  Further, in the 
pooled analysis (Table 3), the SIR decreased from 1.72 (95% CI 1.51 to 1.95) to 1.21 (95% CI 
1.01 to 1.45) after excluding NMSC. Moreover, part of the residual cancer risk after 
excluding NMSC can be attributed to post-transplant malignancies, with the SIR post-
transplant of 2.12 (95% CI 1.01 to 4.44) in the present study and 4.31 (95% CI 1.17 to 11.04) 
in that by van Daalen et al. [19].  
In the organ-specific sub-analysis, the SIR of NMSC was 3.40 (95% CI 1.62 to 7.14), 
which is consistent with that of previous studies [5, 9, 11, 13, 14, 19]. An increased risk of 
NMSC is observed in immunocompromised patients and associated with both environmental 
factors as chronic human papillomavirus infection [26-29] and a direct effect of individual 
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immunosuppressant, e.g. azathioprine [19, 30]. A significantly increased hematologic cancer 
risk was also found (SIR, 3.52; 95% CI 1.32 to 9.37). Traditionally, CYC use was associated 
with a very high risk of acute myelogenous leukaemia (AML) [9, 14, 31]. Interestingly, no 
case of AML was observed in our cohort, and the increased haematologic malignancy risk 
was caused by 2 cases of myelodysplastic syndrome and 2 cases of chronic lymphocytic 
leukaemia. To what extent these cases are related to CYC-based therapy or 
immunosuppression specifically is unclear [32]. In comparison, Zycinska et al. found an 
increased AML risk in their study (SIR, 4.3; 95% CI 2.1 to 11.7). Notably, oral CYC was 
used in the majority of their patients, and 22% received >36 g of cumulative CYC dosage. In 
addition, a significantly increased urothelial cancer risk was also found in their study, in 
contrast to those of other recent groups (SIR, 3.4; 95% CI 1.6 to 5.2) [11].  
Some previous groups have indicated that the cancer risk, perhaps caused by a higher 
tendency of relapses and thus higher cumulative immunosuppressive drug doses, is higher in 
C-ANCA than in P-ANCA positive patients [5, 13]. In contrast, we observed no significantly 
increased risk in these subgroups compared to the general population.  
An important measure to reduce cancer risk in patients with AAV has been replacing 
CYC with azathioprine for maintenance treatment. This practice change occurred around 
2003 concurrent with the publication of the CYCAZAREM study [23, 33]. In the present 
study cohort SIR of cancer was not significant increased, neither in the 1988-2002 nor in the 
2003-2012 time periods. Of notice, in a study including a sub-group of the 1988-2002 cohort, 
cumulative doses of CYC were found fairly low, median 17 grams in intravenous CYC 
treated patients [34].       
The findings by van Daalen et al. indicate that rituximab use is associated with a 
substantially lower risk of malignancy. However, this difference was primarily related to 
excess NMSC cases. The calculated SIR of cancer, except NMSC, was 1.14 (95% CI 0.49 to 
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2.25) with CYC and 0.88 (95% CI 0.11 to 3.19) with rituximab treatment. Thus, the SIR of 
cancer, except NMSC, was only 1.30-fold higher (CI not reported by van Daalen et al.) in the 
CYC group than in the rituximab group. Further, the SIR of cancer, except NMSC, was only 
marginally higher in the present CYC-treated study cohort than in the rituximab group in their 
study, estimated SIR of 0.96 (95% CI 0.69 to 1.34) and 0.88 (95% CI 0.11 to 3.19), 
respectively. Finally, no adjustment for post-transplantation malignancies has been performed 
when comparing CYC- and rituximab-treated patients [19]. In summary, whether replacing 
low-dose CYC regimens with rituximab would have a beneficial effect on non-NMSC 
malignancy risk remains uncertain.  
NMSC occurrence is still substantially increased in patients with AAV. Although 
NMSC by no means should be considered as an inconsequential morbidity, deaths caused by 
these tumours are rare [35]. A number of measures can be taken to reduce the risk and 
morbidity related to NMSC in immunosuppressed patients; the most important measures 
include limiting sun exposure of the skin and vigilant monitoring with early NMSC detection 
and treatment when they appear. Interestingly, van Daalen et al. observed that rituximab use 
is associated with a lower NMSC risk than CYC use, which represents a new possible 
solution to such complication in patients with AAV [19]. However, the decision to replace 
CYC with rituximab as the first-line treatment in patients with AAV must also include 
considerations, such as efficacy, treatment-related complications, and cost-benefit.  
The major strengths of the present study include its population-based approach and 
identification of patients with AAV from quality registries with histologic and serologic data. 
Information on expected and observed cancer cases was retrieved from the same registry, the 
NCR, which limits potential information biases in the SIR calculation. The NCR also has high 
accuracy and only few missing cases owing to mandatory reporting of cancer cases. 
Moreover, the pooled analysis strengthens the statistical power and increases the detection 
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rate of significant differences. Some weaknesses of our study must be admitted. Most 
importantly, we could not correlate our findings to the cumulative CYC doses administered. 
Treatment data were unavailable in the NKBR. However, we have shown from previous 
reports of this cohort that these patients have received therapy according to international 
recommendations [22-24]. Another weakness is the lack of information regarding extra-renal 
and relapsing disease. Relapsing disease in particular is associated with increased treatment 
length and cumulative doses of immunosuppressive drugs that might affect risk of cancer 
development. Also, owing to a lack of sufficient data, we could not calculate pooled SIRs for 
single-site cancers or for malignancy after excluding post-transplant cancers.  
 
In summary, we have demonstrated that the risk of malignancy in patients with AAV 
and glomerulonephritis is not significantly increased. However, significantly increased 
NMSC, hematologic malignancy, and post-transplantation cancer risks were found. These 
findings indicate the presence of associations, although relatively weak, between 
immunosuppression and cancer development. However, recently published data suggest that 
substituting CYC with rituximab could eliminate the risk of developing NMSC. Our findings 
confirm that the long-term international efforts of developing CYC-minimising strategies had 
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Table 1.  Baseline demographics of 419 Norwegian patients with AAV 
 
Table 2A. Standardised incidence ratios for cancers in all sites in the study population 
 
Table 2B. Standardised incidence ratios for the most common organ-specific cancers in the 
study population 
 
Table 3. Studies on cancer incidence in patients with AAV 
 
Legend to figure  
Figure 1. Forest plot showing the risk of malignancy except for non-melanoma skin cancer in 
observational studies of patients with ANCA-associated vasculitis.  
SIR, standardised incidence ratio; 95% CI, 95% confidence interval 
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Table 1.  
Characteristic Total Non-Malignancy Malignancy P-value 
Age (median, IQR) 62 (49-72) 61 (48-72) 65 (56-73) 0.04 
Male sex (%) 229 (55%) 200 (53%) 29 (71%) 0.03 
eGFR (median, IQR) 23 (11-46) 24 (11-47) 19 (9-39) 0.29 
C-ANCA positivity  237 (57%) 213 (56%) 24 (59%) 0.89 
AAV, ANCA-associated vasculitis; IQR, interquartile range; eGFR, estimated glomerular 





Table 2A.  
Characteristic Observed Expected SIR 95% CI 
All 41 37.5 1.09 0.81 to 1.49 
Non-NMSC 34 35.4 0.96 0.69 to 1.34 
Sex 
    
 Male 29 22.9 1.27 0.88 to 1.83 
 Female 12 14.6 0.82 0.47 to 1.44 
Follow-up period     
 0-1 year 3 4.3 0.70 0.22 to 2.16 
 1-5 years 22 14.4 1.53 1.01 to 2.32 
 5-10 years 11 11.1 0.99 0.55 to 1.78 
 >10 years 5 7.6 0.66 0.27 to 1.57 
Transplantation     
 Yes 7 3.3 2.12 1.01 to 4.44 
 No 34 34.2 0.99 0.71 to 1.39 
ANCA serology     
 C-ANCA 24 20.6 1.17 0.78 to 1.74 
 P-ANCA 17 16.9 1.01 0.63 to 1.62 
Study period      
 1988-2002 26 22.7 1.14 0.78-1.68 
 2003-2012 15 14.8 1.02 0.61-1.68 
SIR, standardised incidence ratio; 95% CI, 95% confidence interval; NMSC, non-melanoma 
skin cancer; C-ANCA, cytoplasmic ANCA; P-ANCA, perinuclear ANCA 
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Table 2B.  
Organs Observed Expected SIR 95% CI 
NMSC 7 2.1 3.40 1.62 to 7.14 
Hematologic 4 1.1 3.52 1.32 to 9.37 
Lung 7 4.0 1.73 0.83 to 3.63 
Colon  2 1.2 1.73 0.43 to 6.93 
Urothelium 3 2.0 1.48 0.47 to 4.59 
Prostate 5 7.0 0.72 0.30 to 1.73 
NHL 1 1.2 0.86 0.12 to 6.12 
SIR, standardised incidence ratio; 95% CI, 95% confidence interval; NMSC, non-melanoma 
skin cancer; NHL, non-Hodgkin lymphoma 
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Figure 1 
 
